Protocol #:  LCI-BRE -H2N -PEPP -001 
TITLE:  A PILOT STUDY OF PACLITAXEL PLUS PEMBROLIZUMAB IN PATIENTS WITH 
METASTATIC HER2 -NEGATIVE BREAST CANCER (THE PePPy TRIAL)  
LAY TITLE:  A STUDY OF PACLITAXEL PLUS PEMBROLIZUMAB IN PATIENTS WITH 
METASTATIC HER2 -NEGATIVE BREAST CANCER  
Coordinating Site: 
Levine Cancer Institute  
1021 Morehead Medical Drive  
Charlotte, NC 28204  
 
Sponsor -Investigator:  
Antoinette R. Tan, MD, MHSc  
Levine Cancer Institute  
1021 Morehead Medical Drive  
Charlotte, NC 28204  
Telephone: (980) 442 -6305  
E-mail: antoinette. tan@carolinas healthcare.org  
 
Statistician:  
James Symanowski, PhD  
Levine Cancer Institute  
1100 Blythe Boulevard  
Charlotte, NC 28204  
Telephone: (980) 442 -2371  
E-mail: james.s ymanowski@carolinashealthcare.org   
 
Investigational drug/device:  Pembrolizumab  
Commercial agent:  Paclitaxel  
Supported by:  Merck Sharp & Dohme Corp,  a subsidiary of Merck & Co., Inc. 
 
Inves tigational New Drug (IND)#: 132 021 
______________________________________________________________________________  
The study will be conducted in compliance with the protocol, ICH -GCP and any applicable 
regulatory requirements.  
ii 
 Confidential  
The information provided in this document is strictly confidential and is intended solely for the 
guidance of the clinical investigation.  Reproduction or disclosure of this document - whether in 
part or in full  - to parties not associated with the clinica l investigation, or its use for any other 
purpose, without the prior written consent of the Sponsor -Investigator is not permitted.  
Throughout this document, symbols indicating proprietary names ( , TM) are not displayed.  
Hence, the appearance of product names without these symbols does not imply that these names 
are not protected.  
 
 
Commercial Agent: Paclitaxel                                 Phase II / Version 5 / 4/13/2021 
PROTOCOL SUMMARY  
A. Study Title  A Pilot Study of Paclitaxel plus Pembrolizumab in Patients with Metastatic 
HER2 -negative Breast Cancer ( The PePPy Trial)  
B. Indication  Metastatic HER2 -negative breast cancer ; no more than three prior lines of 
cytotoxic chemotherapy  for metastatic disease  
C. Clinical Phase  Phase II   
 
D. Summary of 
Rationale  
 
 Pembrolizumab is a potent and highly selective humanized monoclonal 
antibody designed to directly block the interaction between PD -1 (programmed 
death -1) and its ligands, PD -L1 and PD -L2. A strategy of combining 
chemotherapy with immunotherapy is a promisi ng approach for treatment of 
HER2 -negative breast cancer.  There is little known about the optimal sequence 
of administration of chemotherapy and immunotherapy in breast cancer. This 
study will evaluate the safety of a phased regimen , paclitaxel only for 2 cycles 
then pembrolizumab and paclitaxel, and a concurrent regimen , 
pembrolizumab given concurrently with paclitaxel upfront.  
E. Study 
Objectives  The primary objective of  this study is to assess the safety and feasibility of the 
two regimens . 
 
Secondary objectives are to assess overall survival (OS), progression -free 
survival (PFS) , objective  response rate (ORR ), duration of response (DoR), and 
disease control rate (DCR) .   
 
Exploratory objectives include assessment of PD -L1 status and genomic profile 
of tumors.  
F. Sample  40 evaluable subjects  
G. Inclusion/  
Exclusion  Inclusion:  
• HER2 -negative metastatic breast cancer  
iii 
 • Age ≥ 18 years  
• ECOG ≤ 2 
• Measurable or evaluable disease  
• Adequate organ and bone marrow function  
 
Exclusion:  
• More than three prior lines of chemotherapy for metastatic disease  
• Pregnant and/or breastfeeding  
• Prior therapy with anti PD -1m, anti PD -L1, anti PD -L2, or other co -
inhibitory T -cell receptor agent  
 
H. Dosage/ 
Dosage 
Form, Route, 
And Dose 
Regimen  Pembrolizumab 200 mg IV over 30 minutes, on day 1 every 21  days  
Paclitaxel 80 mg /m2 IV over 6 0 minutes, on days 1 and 8 every 21 days  
 
  
iv 
 SCHEMA  
LCI-BRE -H2N -PEPP -001: A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients with 
Metastatic HER2 -Negative Breast Cancer (The PePPY Trial)  
Sponsor -Investigator: Dr. Antoinette Tan  
 

v 
 LIST OF ABBREVIATIONS  
Abbreviation  Spelled out abbreviation . List ed in alphabetical order.  
AST  Aspartate aminotransferase  
ALT  Alanine aminotransferase  
BRAF  B-Raf proto -oncogene  
CTCAE  Common terminology criteria for adverse events  
CTLA -4 Cytotoxic T -lymphocyte associated protein 4  
CrCL  Creatinine clearance  
CNS  Central nervous system  
CTMS  Clinical trials management system  
DNA  Deoxyribonucleic acid  
ECG  Electrocardiogram  
ECIs  Events of clinical interest  
eCRFs  Electronic case report forms  
ER Estrogen receptor  
GFR  Glomerular filtration rate  
HER2  Human epidermal growth factor receptor type 2  
HIV Human immunodeficiency virus  
Ig Immunoglobulin  
ITSM  Immunoreceptor tyrosine -based switch motif  
IV Intravenous  
LCI Levine Cancer Institute  
mAb  Monoclonal antibody  
MBC  Metastatic breast cancer  
MTD  Maximum tolerated dose  
NE Not evaluable  
vi 
  
 
 
  NSCLC  Non-small cell lung cancer  
ORR  Objective response rate  
OS Overall survival  
PD-1 Programmed death 1  
PD-L1 Programmed death ligand 1  
PFS Progression free survival  
PK Pharmacokinetic  
PO By mouth; taken orally  
PR Progesterone receptor  
Q2W  Every 2 weeks  
Q3W  Every 3 weeks  
RECIST  Response evaluation criteria in solid tumors  
SCLC  Small cell lung cancer  
SHP-1, SHP -2 Src-Homology 2 domain containing phosphatase -1 and -2 
TAMs  Tissue associated macrophages  
TILs  Tissue infiltrating lymphocyte  
TNBC  Triple -negative breast cancer  
Tregs  Regulatory T cells  
ULN  Upper limit of normal  
v-type Variable -type 
WOCBP  Women of childbearing potential  
vii 
 TABLE OF CONTENTS  
 
PROTOCOL SUMMARY  ................................ ................................ ................................ ...........  ii 
SCHEMA  ................................ ................................ ................................ ................................ ...... iv 
LIST OF ABBREVIATIONS  ................................ ................................ ................................ ..... v 
TABLE OF CONTENTS  ................................ ................................ ................................ ..........  vii 
1. OBJECTIVES  ................................ ................................ ................................ ....................  1 
1.1. Primary Objective  ................................ ................................ ................................ ............  1 
1.2. Secondary Objectives  ................................ ................................ ................................ ....... 1 
1.3. Safety Objectives ................................ ................................ ................................ ..............  1 
1.4. Exploratory Objectives  ................................ ................................ ................................ ..... 1 
2. BACKGROUND  AND RATIONALE  ................................ ................................ .............  1 
2.1. Metastatic HER2 -negative Breast Cancer  ................................ ................................ ........  1 
2.2. Taxanes in Breast Cancer  ................................ ................................ ................................ . 2 
2.3. Programmed Death -1 (PD -1) Checkpoint Inhibitor as a Strategy for Treatment of Breast 
Cancer ................................ ................................ ................................ ................................ ..........  3 
2.4. Pembrolizumab ................................ ................................ ................................ .................  4 
2.5. Chemotherapy in Combination with Immunotherapy  ................................ ......................  8 
2.6. Study Rationale  ................................ ................................ ................................ ..............  12 
3. PATIENT  SELECTION  ................................ ................................ ................................ . 12 
3.1.    Accrual ……………………………………………………………………………… .. 13  
3.2. Inclusion  Criteria  ................................ ................................ ................................ ............  13 
3.3. Exclusion Criteria  ................................ ................................ ................................ ...........  14 
4. INVESTIGATIONAL PLAN  ................................ ................................ .........................  16 
4.1. Milestone Date Definitions  ................................ ................................ ............................  16 
4.2.   Overall Study Design  ………………………………………………………………….  16 
4.3. Randomization/Registration/Enrollment  ................................ ................................ ........  17 
4.4. Pre-Treatment  ................................ ................................ ................................ .................  17 
4.5. Treatment  ................................ ................................ ................................ .......................  24 
4.6. End of Treatment  ................................ ................................ ................................ ............  25 
viii 
 4.7. Follow -up ................................ ................................ ................................ .......................  26 
4.8. Subject Withdrawal and Off Study  ................................ ................................ ................  26 
4.9. Screen Failures/Subject Replacements ................................ ................................ ...........  27 
5. STUDY CALENDAR  ................................ ................................ ................................ ...... 28 
6. TREATMENT PLAN  ................................ ................................ ................................ ...... 30 
6.1. Drug Dosage and Administration  ................................ ................................ ...................  30 
6.2. Paclitaxel  ................................ ................................ ................................ ........................  30 
6.3. Pembrolizumab ................................ ................................ ................................ ...............  33 
6.4. Treatment Administration  ................................ ................................ ..............................  33 
6.5. Concomitant Medications  ................................ ................................ ..............................  33 
6.6. Duration of Therapy  ................................ ................................ ................................ ....... 33 
6.7. Drug Accountability  ................................ ................................ ................................ ....... 34 
6.8. Destruction  ................................ ................................ ................................ .....................  33 
7. DOSE MODIFICATIONS  ................................ ................................ ..............................  34 
7.1. Pembrolizumab ................................ ................................ ................................ ...............  34 
7.2. Paclitaxel  ................................ ................................ ................................ ........................  36 
8. TREATMENT -RELATED ADVERSE EVENTS  ................................ ........................  38 
8.1. Adverse Events Related to Pembrolizumab  ................................ ................................ ... 38 
9. DATA AND SAFETY MONITORING PLAN  ................................ .............................  44 
9.1. Safety Monitoring  ................................ ................................ ................................ ..........  44 
9.2. Data Quality Assurance  ................................ ................................ ................................ .. 44 
9.3. Communication Between Sites  ................................ ................................ ......................  45 
10. SAFETY DATA COLLECTION, RECORDING AND REPORTING ......................  45 
10.1.  Unanticipated Problem Definition  ................................ ................................ .................  45 
10.2.  Adverse Event  ................................ ................................ ................................ ................  45 
10.3. Suspected Adverse Reaction Definition  ................................ ................................ .........  47 
10.4.  “Unexpected” Definition  ................................ ................................ ................................  47 
10.5.  “Serious” and “Life -Threatening” Definitions  ................................ ...............................  47 
10.6.  Serious Adverse Event Definition  ................................ ................................ ..................  48 
10.7.  Safety Reporting to the Sponsor -Investigator  ................................ ................................  48 
ix 
 10.8.  Safety Reporting to the FDA  ................................ ................................ ..........................  49 
10.9.  Safety Reporting to the IRB  ................................ ................................ ...........................  49 
10.10.  Safety Reporting to Merck……………………………………………………………..49   
11. MEASUREMENT OF EFFECT  ................................ ................................ ....................  50 
11.1.  Anti-tumor Effect – Solid Tumor  ................................ ................................ ...................  50 
12. STATISTICAL CONSIDERATIONS  ................................ ................................ ...........  55 
12.1.  Sample Size  ................................ ................................ ................................ ....................  55 
12.2.  Endpoint Definitions  ................................ ................................ ................................ ...... 55 
12.3.  Analysis Populations  ................................ ................................ ................................ ...... 57 
12.4.  Analysis Methods  ................................ ................................ ................................ ...........  57 
12.5.  Interim Analyses  ................................ ................................ ................................ ............  59 
13. STUDY COMPLETION  ................................ ................................ ................................ . 59 
13.1.  Completion  ................................ ................................ ................................ .....................  59 
13.2.  Termination  ................................ ................................ ................................ ....................  60 
14. RETENTION OF RECORDS  ................................ ................................ ........................  60 
15. ETHICAL AND LEGAL ISSUES  ................................ ................................ ..................  60 
15.1.  Ethical and Legal Conduct of the Study ................................ ................................ .........  60 
15.2.  Confidentiality  ................................ ................................ ................................ ................  61 
16. PUBLICATION POLICY  ................................ ................................ ...............................  61 
REFERENCES  ................................ ................................ ................................ ............................  62 
APPENDICES  ................................ ................................ ................................ .............................  30 
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
1 
 1. OBJECTIVES  
 
1.1. Primary Objective  
The primary obje ctive of this study is to assess the safety and feasibility of the following two 
regimens: Cohort A) phased regimen of pembrolizumab in which paclitaxel is followed by 
paclitaxel plus pembrolizumab and Cohort B) concurrent regimen of paclitaxel plus 
pembrolizumab.   The primary safety objective is to evaluate the overall grade 3 or 4 
treatment -related adverse  event  rate for each cohort and compare them to relevant historical 
controls.  
 
1.2. Secondary Objectives  
Secondary objectives are to assess  overall survival (OS), progression -free survival  (PFS) , 
objective  response rate (ORR)  duration of response (DoR), and disease control rate (DCR) .  
PFS, ORR , DoR, and DCR  will be evaluated using RECIST 1.1 criteria.     
 
1.3. Safety Objectives  
The safety objective s are to evaluate each cohort in terms of study drug administration, 
adverse events assessed by NCI Common Terminology Criteria for Adverse Events  version 
4.0, serious adverse events including deaths on study, and laboratory parameters.  
 
1.4. Exploratory Objectives  
Exploratory objectives include  
• Assessment of PFS, ORR , DoR , and DCR using the immune -related RECIST 
(irRECIST) criteria  
• Assessment of t umor -associated PD-L1 (programmed death -ligand 1) 
expression  
• Assessment of t issue infiltrating lymphocytes (TILs) in tumor  
• Genomic analyses  of the tumor  
• Evaluation of circulating tumor DNA  
• Colle ction of b iomarkers in blood , including but not limited to cytokines  
• Development of a patient derived xenograft model if sufficient tumor is 
available  
 
2. BACKGROUND  AND RATIONALE  
 
2.1. Metastatic HER2 -negative Breast Cancer  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
2 
 An estimated  231,840 new cases of breast cancer are expected to be  diagn osed in the United 
States during 2015 and it is estimated that there will be 4 0,730 deaths from breast cancer .1  
Single agent or combination chemotherapy produces response rates of 40 -70% in the 
treatment of advanced breast cancer.  Although numerous regimens are effective in palliating 
symptoms and inducing tumor regression, the complete response ra te is less than 20%.  
Moreover, the median duration of response is nine months  with a median survival of 12 -36 
months.  M ost responses are of limited duration and nearly all patients with stage IV disease 
eventual ly die of disease progression .  Therefore, the treatment of patients with metastatic 
human epidermal growth factor receptor type 2 ( HER2 )-negative breast cancer warrants 
investigation of novel therapeutic strategies.  
The treatment algorithm for patients with metastatic breast cancer  (MBC ) is based on several  
factors which include clinical, pathologic, and histologic characteristics such as the presence 
or absence of human e pidermal growth factor 2 amplification, hormone receptor status, prior 
response to endocrine  therapy, disease extent and locatio n of metastatic disease, pace of 
disease progression, and time to relapse since completion of adjuvant chemotherapy.  While 
endocrine therapy is the preferred initial treatment for patients with hormone rec eptor -
positive disease, cytotoxic chemotherapy becomes appropriate for those with hormone 
refractor y disease or rapidly progressive disease to achieve a rapid rate of response. For 
patients with triple -negative breast cancer, or breast cancer that is estrogen receptor (ER) - 
negative, proge sterone receptor (PR) -negative, and HER2 -negative, chemotherapy at present  
is the mainstay of treatment.  
 
2.2. Taxanes in Breast Cancer  
Taxanes are among the most active of chemotherapy agents for the treatment of M BC in 
terms of response rates or survival, ba sed on a metaanalysis of three randomized trials 
comparing a taxane - with an anthracycline .2  The role of paclitaxel in the treatment  of breast 
cancer has been well established  in both the adjuvant and metastatic settings.  The response 
rates for paclitaxel administered as a  single agent to patients with M BC are approximat ely 
25% in firstline - treatment .3,4 
 
The most common practice is to administer paclitaxel on a weekly schedul e based on the 
results of a 2010 meta -analysis, which showed that compared wit h every three -week 
treatment, weekly administration of paclitaxel resulted in an improvement in overall survival 
(OS, hazard ratio [HR] 0.78, 95% CI 0.67 -0.89) .6  Allergic reactions are a potential side 
effect of treatment with paclitaxel as a result of the composition of paclitaxel, which is mixed 
with Cremophor. At most institutions, s teroid premedication ( IV dexamethasone  8-12 mg 30 
minutes prior to the paclitaxel dose ) is administered, although it can usually be discontinued 
if the first tw o or three doses are tolerated.  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
3 
  
2.3. Programmed Death -1 (PD -1) Check point Inhibitor as a Strategy for Treatment 
of Breast Cancer  
Encouraging clinical data emerging in the field of tumor immunotherapy have 
demonstrated  that therapies focused on enhancing Tcell - responses against cancer can result 
in a significant survival benefit in patients with advanced malignancies .7-9 
The PD -1 receptor -ligand interaction is a major pathway hijacked by tumors to suppress 
immune control .10 The normal function of PD -1, expressed on the cell surface of activated T 
cells under healthy conditions, is to down -modulate unwanted or excessive immune 
responses, including autoimmune reactions.  PD-1 is an immunoglob ulin (Ig) superfamily 
member related to CD28 and Cytotoxic T -Lymphocyte  Associated Protein 4 (CTLA -4), 
which has been shown to negatively regulate antigen receptor signaling upon engagement of 
its ligands (PD -L1 and/or PD -L2). PD-1 and family members are t ype I transmembrane 
glycoproteins containing an Ig Variable -type (V -type) domain responsible for ligand binding 
and a cytoplasmic tail which is responsible for the binding of signaling molecules . 
Following T cell stimulation, PD -1 recruits the tyrosine pho sphatases Src -Homology 2 
domain -containing phosphatase -1 and -2 (SHP -1 and SHP -2) to the ITSM within its 
cytoplasmic tail, leading to the dephosphorylation of effector molecules, such as CD3ζ, 
Protein Kinase C theta (PKCθ ) and Zeta -chain -Associated Protein kinase 70 (ZAP70), which 
are involved in the -Homology 2 domain -containing phosphatase -1 and -2 (SHP -1 and SHP -
2) to the ITSM within its cytoplasmic tail, leading to the dephosphorylation of e ffector 
molecules, such as CD3ζ, Protein Kinase C theta (PKCθ) and Zeta -chain -Associated Protein 
kinase 70 (ZAP70), which are involved in the CD3 T cell signaling cascade . PD-1 was 
shown to be expressed on activated lymphocytes, including peripheral CD4+ a nd CD8+ T 
cells, B cells, regulatory T cells (Tregs) and Natur al Killer (NK) cells .12 CD3 T cell signaling 
cascade. PD -1 was shown to be expressed on activated lymphocytes, including peripheral 
CD4+ and CD8+ T cells, B  cells, regulatory T cells (Tregs) and Natural Killer (NK) cells.  
The ligands for PD -1 (PD -L1 and PD -L2) are constitutively expressed or can be induce d in a 
variety of cell types . PD-L1 is expressed at low levels on various non -hematopoietic tissues, 
most  notably on vascular endothelium, whereas PD -L2 protein is only detectably expressed 
on antigen -presenting cells found in lymphoid tissue or chroni c inflammatory 
environments .13   
Binding of either PD -1 ligand to PD -1 inhibits T cell activation triggered through the T cell 
receptor. PD -L2 is thought to control immune T cell activation in lymphoid organs, whereas 
PD-L1 serves to dampen unwarranted T cell function in peripheral tissues.  Although healthy 
organs express little (if any) PD -L1, a variety of cancers were demo nstrated to express 
abundant levels of  this T cell inhibitor,  which, via its interaction with the PD -1 receptor on 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
4 
 tumor -specific T cells, plays a critical role  in immune evasion by tumors .14 As a 
consequence, the PD -1/PD -L1 pathway is  an attractive target for therape utic intervention  in 
cancer .15 
The immu ne system plays an important and complex role in the biology of breast cancer.  
There is preclinical and clinical evidence suggesting that immunotherapy has the potential to 
improve clinical outcomes for patients with breast cancer. Immune modulatory agents have 
several unique features that make them  attractive to combine with standard cytotoxic agents, 
and includes the observation that cancer immunotherapies cause fewer side effects, enabling 
them to be given for longer periods of ti me and in combination with other agents without 
added toxicity.  There also is p otentially less likelihood to develop resistance to 
immunotherapy because of the immune system’s ability to simultaneously target multiple 
cancer antigens and adapt to mutating  cancer cells.  
 
2.4. Pembrolizumab  
Pembrolizumab (Keytruda®) is a potent and highly selective humanized monoclonal antibody 
(mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD -1 
and its ligands, PD -L1 and PD -L2.  This blockade  enhances functional activity of the target 
lymphocytes to facilitate tumor regression and ultimately immune rejection.  
 
2.4.1.  Nonclinical Studies  
The noncl inical strategy of the pembrolizumab  program was to demonstrate in  vitro  and 
in vivo activity, to determi ne in vivo pharmacokinetic (PK) behavior, to demonstrate an 
acceptable safety profile, and to identify a Phase I starting dose.  Comprehensive 
pharmacology, PK, and toxicology evaluations were thus undertaken with 
pembrolizumab . 
The safety, pharmacokinetic s, and toxicokinetics  of pembrolizu mab were investigated in 
mice and cynomolgus monkeys to support IV  administration and to aid in  projecting the 
appropriate starting dose in humans.  Given the high amino acid homology of the 
extracellular regions of PD -1 between cynomolgus monkey and human, the cynomolgus 
monkey was selected as the primary and relevant n onclinical model for understanding the 
toxicology of pembrolizumab.  
Overall, the nonclinical pharmacokinetics and toxic okinetics observed for 
pembrolizumab  supported entry into clinical studies, including providing adequate safety 
factors for the proposed Phase I starting doses.  T he results of the preclinical program 
were consistent with the anticipated  activity of pembrolizumab to enhance the functional 
activity of tumor -infiltrating lymphocytes to induce tumor regression and ultimately 
immune rejection by blocking the interaction between PD -1 and its ligands, PD -L1 and 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
5 
 PD-L2 and supported entry into clinical trials in pati ents. Refer to the pembrolizumab  
Investigator’s Brochure for details on the nonclinical studies .16 
 
2.4.2.  Clinical Studies – Approval  of Pembrolizumab  
Pembrolizumab  was approved in the United States o n September 4, 2014  by the FDA  for 
the treatment of patients with unresectable or metastatic melanoma and disease 
progression following ipil imumab and, if BRAF V600 mutation positive, a BRAF 
inhibitor.  This indication is approved under accelerated approval based on tumor 
response rate and durability of response.  
Approval was based on the results of a multicenter, open -label, randomized (1:1), dose -
comparative, activity -estimating cohort conducted within Trial P N001, which was the 
first-in human  dose cohort escalation study of pembroliz umab that enrolled subjects into 
4 parts (Parts A -D, A = any advanced solid tumor, B = melanoma, C =  NSCLC, and D = 
melanoma, 2 dos es of pembrolizuma b). 
 
In this cohort, 173 patients with unresectable or metastatic melanoma with disease 
progression within 24 weeks of the last dose of ipilimumab and, if BRAF V600 mutation 
positive, prior treatment with a BRAF inhibitor, were randomized to receive 
pembrolizumab 2 mg/kg (n=89) or 10 mg/kg (n=84) intravenously once every 3 weeks 
until disease  progression or unacceptable toxicity.  
  
Key exclusion criteria were an autoimmune disease, a medical condition that required 
immunosuppression, and/or a history o f severe immune -mediated adverse reactions from 
treatment with ipilimumab.  Seve re immune -mediated adverse reactions were defined as 
any CTCAE Grade 4 toxicity requiring treatment with corticosteroids or Grade 3 toxicity 
requiring corticosteroid treatment (greater than 10 mg/day prednisone or equivalent d ose) 
for greater than 12 weeks . 
 
The major efficacy endpoints were confirmed o bjective  response rate (ORR) according to 
Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as assessed by a blinded 
independent review committee and duration of response (DOR).  In the lower dose that 
was ultima tely appr oved, 2 mg/kg, the ORR was 26 % (95% CI, 1 7-37%). A total of 21 
patients showed a response, including one patient with a complete response. Three of the 
patients (14%) had disease progression at 2.8 months, 2.9 months, and 8.2 months after 
the initial response. The other 18 patients (86%) showed durable responses of 1.4 to 8.5 
months. Of note, eight patients (38%) had ongoing responses of ≥ 6 months. Similar 
ORR results were observed in the 10 mg/kg arm.17 Treatment was well tolerated, with 
similar safety profiles in the 2 mg/kg and 10 mg/kg groups and no d rug-related deaths. 
The most common drug -related adverse events of any grade in the 2 mg/kg and 10  mg/kg 
groups were fatigue (33% vs 37%), pruritus (26% vs 19%), and rash (18% vs 18% ). 
Grade 3 fatigue, reported in five (3%) patients in the 2 mg/kg pembroli zumab group, was 
the only drug -related grade 3 to 4 adverse event reported in more than one patient.   
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
6 
 Additionally, two multicenter, randomized, controlled therapeutic confirmatory trials in 
patients with unresectable or metastatic melanoma, ipilimumab re fractory (KEYNOTE -
002/Trial P002) and ipilimumab -naive (KEYNOTE -006/Trial P006), evaluated co -
primary endpoints of progression -free survival and overall survival, and have results .   
 
In the KEYNOTE -002 trial, 540 patients with ipilimumab -refractory advanced melanoma 
were randomly assigned to pembrolizumab at 2 mg/kg (n = 180), 10 mg/kg (n = 181), or 
chemotherapy (n = 179) .18  Chemotherapy was selected by investigators and consisted 
primarily of paclitaxel plus carboplatin, paclitaxel, carboplatin, dacarbazine, or 
temozolomide. Pembrolizumab was administered every 3 weeks.  Both pembrolizumab 
arms were significantly superior to chemotherapy ( P <.0001). At the recommended 2 -
mg/kg dose, pembrolizuma b demonstrated a PFS of 34% at 6 months and 24% at 9 
months. In the chemotherapy arm, the PFS was 16% and 8%, at the 6 - and 9 -month 
analyses, respectively.  
 
At the 2 -mg/kg dose, the ORR with pembrolizumab was 21% with a median duration of 
respo nse that was not yet reached. The ORR in the chemotherapy arm was 4%, the 
median response duration was 37 weeks. At the analysis, 63% of responses were 
ongoing. Treatment was relatively well tolerated, with grade 3 -5 adverse events reported 
in 11 and 14 pe rcent of the pembrolizumab  treatment arms, and 26 percent of those 
managed with chemotherapy. The most common pembrolizumab -related adverse events 
were fatigue,  pruritus, and rash. Grade 3 immune related toxicity was reported in two 
patients treated with pembrolizumab 2 mg/kg (hepatitis, hypophysitis), and in eight 
patients given pembrolizumab 10 mg/kg (hepatitis, colitis, pneumonitis, and iritis or 
uveitis).  
 
In the phase III KEYNOTE -006 trial, pembrolizumab  demonstrated significantly longer 
PFS and improved overall survival compared with ipilimumab  as immunotherapy in 
patients with advanced melanoma .19 This trial included 834 pat ients with unresectable 
stage III or IV advanced melanoma who had received no more than one prior systemic 
therapy. Patients were randomized to receive four cycles of ipilimumab at 3 mg/kg every 
3 weeks (n = 278), 10 mg/kg of pembrolizumab every 3 weeks (n  = 277), or 10 mg/kg of 
pembrolizumab every 2 weeks (n = 279 ). Patient  response in KEYNOTE -006 was 
assessed at week 12 and every 6 weeks thereafter by RECIST 1.1. Median follow -up was 
8 months. Both doses of pembrolizumab were found to be superior to ipili mumab.  At a 6 -
month assessment, the PFS with pembrolizumab was 47% and 46% in the 2 - and 3 -week 
arms respectively. For ipilimumab, the PFS rate was 27%. At 9 months, PFS rates were 
40% and 42% compared with 16%, in the 2 -week, 3 -week, and ipilimumab arms, 
respectively. In  the 3 -week pembrolizumab arm, the 1 -year OS rate was 68% compared 
with 58% for ipilimumab (HR, 0.69). In the 2 -week arm, the 1 -year OS rate was 74% 
(HR, 0.63). The objective response rates (ORR) were 33.7 % and 32.9%, in the 2 - and 3 -
week  arms. In the ipilimumab arm, the ORR was 11.9 %. The  toxicity profiles of the 
agents were consistent with other reported studies of the two checkpoint agents. Though 
pembrolizumab was administered for a longer duration, rates of grade 3 -5 adverse e vents 
were  numerically lower th an in the ipilimumab arm (11.7% vs 19.9%). There were no 
differences in efficacy parameters in any patient subsets, with the exception of a lack of 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
7 
 improvement in overall survival associated with pembrolizumab  in those patients whose 
tumors did not express PD -L1 using the Merck immunohistochemistry assay. The PFS, 
overall survival, response rates, and side  effects profiles were fully consistent with those 
seen in earlier trials with both pembrolizumab and ipilimumab .  
 
These t rials demonstrate  the efficacy of pemb rolizumab in the treatment of advanced 
melanoma. Ongoing clinical studies are being conducted in a number of other advanced 
solid tumor indications , including breast cancer.  
 
2.4.3.  Clinical Studies in Breast Cancer with Pembrolizumab  
In the first report of clinic al activity of an immune checkpoint inhibitor in metastatic 
breast cancer, a multi -center, non -randomized p hase Ib trial (Keynote  012) showed that 
single -agent pembrolizumab given at 10 mg/kg Q2W is a well -tolerated and effective 
treatment with significant  therapeutic activity in a subset of heavily pre -treated patients 
with metastatic triple -negative breast cancer  (TNBC)  20.  
 
The phase Ib study enrolled 32 patients with TNBC who had recurrent or metastatic 
disease (47% of which had more than three lines of previous chemotherapy) with PD -L1 
expression in their  tumor (58% of all patients screened had PD -L1- positive tumors .). 
Pembrolizumab was administered 10 mg/kg intravenously every 2 weeks, and treatment 
could continue indefinitely  as long as patients were stable and their disease was not 
clearly progressing as assessed by RECIST v1.1 every 8 weeks. Treatment with PD -1 
blockade was tolerable, with 56% of patients reporting an adverse event, but only 16% 
with grade 3 –5 toxicity. There was one treatment -related death caused by disseminated 
intrav ascular coagulation. The ORR was 19% (27 patients were evaluable for response) 
with one (4%) complete response, four (15%) partial responses, and seven patients (26%) 
with stable disease. Of note, the median time to response was 18 weeks (range, 7 to 32).  
 
There is an international, multi -center phase II clinical trial of pembrolizuma b as 
monothera py that is currently enrolling patients with metastatic triple -negative breast 
cancer (Keynote 086;  [STUDY_ID_REMOVED]) .  The results of this trial and others that are 
evaluating checkpoint inhibitors in the treatment of metastatic breast cancer  will help 
further the clinical development of immunotherapeutic agents in this breast cancer 
subtype.  
 
2.4.4.  Rationale for  Flat Dosing of  Pembrolizumab  
An open -label Phase I trial (Protocol 001) has been conducted to evaluate the safety and 
clinical activity of single agent pembrolizumab.  The dose escalation portion of that trial 
evaluated three dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered e very 2 weeks 
(Q2W) in subjects with advanced solid tumors.  All three dose levels were well tolerated 
and no dose -limiting toxicities were observed.  This first in human study of 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
8 
 pembrolizumab showed evidence of target engagement and objective evidence of tumor 
size reduction at all dose levels (1 mg/kg, 3 mg/kg and 10 mg/kg Q2W).  No MTD has 
been identified to date.  Recent data from other clinical studies within the pembrolizumab 
program has shown that a lower dose of pembrolizumab and a less frequent sch edule may 
be sufficient for target engagement and clinical activity. The currently approved dose of 
pembrolizumab is 2 mg/kg IV over 30 minutes every 3 weeks.   
 
PK data analysis of pembrolizumab administered Q2W and Q3W showed slow systemic 
clearance, limi ted volume of distribution, and a long half -life16.  Pharmacodynamic data 
(IL-2 release assay) suggested that peripheral target engagement is durable (>21 days).  
This early PK and pharmacodynamic data provides scientific rationale for evaluating a 
Q3W dosing schedule.   
 
A population pharmacokinetic analysis has been performed us ing serum concentration 
time data from 476 patients. Within the resulting population PK model, clearance and 
volume parameters of pembrolizumab were found to be dependent on body weight. The 
relationship between clearance and body weight, with an allometri c exponent of 0.59, is 
within the range observed for other antibodies and would support both body weight 
normalized dosing or a fixed dose across all body weights.  Pembrolizumab has been 
found to have a wide therapeutic range based on the melanoma indicat ion.  The 
differences in exposure for a 200 mg fixed dose regimen relative to a 2 mg/kg Q3W body 
weight based regimen are anticipated to remain well within the established exposure 
margins of 0.5 – 5.0 for pembrolizumab in the melanoma indication. The expo sure 
margins are based on the notion of similar efficacy and safety in melanoma at 10 mg/kg 
Q3W vs. the proposed dose regimen of 2 mg/kg Q3W (i.e. 5 -fold higher dose and 
exposure). The population PK evaluation revealed that there was no significant impact of 
tumor burden on exposure. In addition, exposure was similar between the NSCLC and 
melanoma indications. Therefore, we do not anticipate  changes in exposure between 
different indication settings.  
 
The choice of the 200 mg Q3W dose of pembrolizumab (fixed  dosing) is based on 
simulations performed using the population PK model of pembrolizumab showing that 
the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally 
consistent with those obtained with the 2 mg/kg dose every 3 weeks, 2 ) will maintain 
individual patient exposures in the exposure range established in melanoma as associated 
with maximal efficacy response and 3) will maintain individual patient ’s exposure in the 
exposure range established in melanoma that are well tolerated  and safe.  
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
9 
 A fixed dose regimen will simplify the dosing regimen to be more convenient for 
physicians and to reduce potential for dosing errors.  A fixed dosing scheme will also 
reduce complexity in the logistical chain at treatment facilities and reduce  wastage.  
 
2.5. Chemotherapy in Combination with Immunotherapy  
Although standard -dose chemotherapy was conventionally thought to suppress the immune 
system directly by decreasing lymphocyte numbers and limiting the expansion of activated 
lymphocytes, it has bee n demonstrated that chemotherapy also has the capacity to be 
leveraged effectively to potentially augment cancer immunity in several ways. For example, 
chemotherapy can decrease tumor burden, generate immunogenic cell death and can interrupt 
mechanisms of immune tolerance.21 
 
Paclitaxel is a common first -line regimen for the treatment of metastatic HER2 -negative 
metastatic breast cancer.22  Paclitaxel therapy has been shown to increase tumor -associated 
macrophages (TAMs) infiltration in breast tumors.23  Paclitaxel has also been shown to 
upregulate PD -L1 expression in breast cancer cells, contributing to immune resistance.24  
Combining pembrolizumab, a hum an monoclonal immunoglobulin G4 antibody which binds 
to PD -1, with paclitaxel in HER2 -negative breast cancer could be synergistic and potentiate 
the effect of chemotherapy via an anti -tumor immune response. In designing combination 
immunotherapy regimens, consideration needs to be given with regards to how chemotherapy 
impacts the immune system in order to guide the dose and schedule for combining 
chemotherapy and immunotherapy. The optimal drug dose and timing in relation to immune -
based therapy in early -phase clinical studies is necessary to help inform the design of future 
phase II and III clinical trials.  
 
The cytotoxic effects of paclitaxel are driven primarily by disturbing the microtubule 
dynamics and inducing apoptosis. In addition to the cytotoxic e ffect on tumor cells, 
paclitaxel has been reported to modulate the host immune system in a number of ways.21 
Regulatory T cells, which down -regulate immune effector activity, have been shown to be 
increased in the peripheral blood of patients with pancreatic, lung and breast cancer, 
potentially suppressing an anti -tumor response.25 
 
Paclitaxel therapy has demonstrated the ability to induce apoptosis and impair these T 
regulatory cells (potential drivers of peripheral tolerance) preferentially, but not effector T 
cells (potential drivers or effectors of tumor -cell killing), which could potentially shift the 
balance to anti -tumor immune activa tion. In addition, immune activation in lung cancer 
patients after paclitaxel treatment was reported and the generation of pro -inflammatory 
cytokines IFN - and IL -2, as well as the expression of T -cell activation markers was 
increased in lung cancer patients after paclitaxel treatment.24 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
10 
  
Consistent with this observation, paclitaxel has been shown to also induce macrophage 
activation and release of inflammatory cytokines in mouse models.26 The perpetuation of an 
effective anti -tumor response requires a pre dominantly effector T -cell activation and further 
expansion, as well as pro -inflammatory cytokine release, which supports cytotoxic T -cell 
activation and a potential anti -tumor effect. This immune activation process may be 
subsequently attenuated and rever sed by PD -1 expression on activated T cells and the PD -L1 
on tumors, conversely supporting T regulation and suppressing and eliminating cytotoxic T 
effectors. In fact, paclitaxel has also been show to upregulate PD -L1 expression, ultimately 
reversing its p otential tumor immune activation.24 PD-1 expression is induced when T cells 
are activated.27 An important role of PD -1 is to limit T cell effector activation and enhance T 
regulatory mechanisms.28 
 
Pembrolizumab blocks the binding of PD -1 expressed on immune cells to its ligand (PD -L1) 
expressed in tumors, blocking of which potentially reverses down -regulation of cellular 
immunity to the tumor. Pembrolizumab has demonstrated promising anti -tumor ac tivity in a 
variety of tumors, including known immunogenic tumors (i.e. melanoma), as well as tumors 
previously considered less immunogenic ( i.e., NSCLC).  Chemotherapy in combination with 
anti-PD-1 has demonstrated enhanced activity against several mouse tumor models 
(Pembrolizumab IB) and clinical results support this combination approach.29  
 
When combining immunotherapy with chemotherapy, it is important to determine the 
optimal dose, schedule and sequence. There is some data on the optimal timing and dose  of 
immunotherapy with chemotherapy. Results from two multicenter phase II lung cancer trials 
showed that a “phased regimen” in which immunotherapy begins after chemotherapy 
resulted in improved progression -free survival, compared with chemotherapy alone.  
 
Combining ipilimumab with paclitaxel and carboplatin,  significantly improved immune -
related progression -free survival (irPFS) compared with chemotherapy alone in a phase II 
study in patients with NSCLC and extensive disease SCLC.29,30 However, the improvement 
in irPFS was only evident when the drugs were given on a phased schedule (e.g., two doses 
of placebo plus paclitaxel/carboplatin followed by four doses of ipilimumab plus 
paclitaxel/carboplatin), not when they were given concurrently. Phased ipilimumab, 
concurrent ipilimumab, and control, respectively, were associated with medi an irPFS of 5.7, 
5.5, and 4.6 months in patients with NSCLC, and 6.4, 5.7, and 5.3 months in patients with 
SCLC. The overall incidence of treatment -related grade 3/4 adverse events was similar 
across the arms, and ipilimumab did not appear to exacerbate th e adverse events associated 
with chemotherapy.  
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
11 
 There is no data with regards to the sequencing of pembrolizumab in relation to 
chemotherapy in the treatment of breast cancer. This pilot study will primarily assess the 
safety of dose and dosing schedule of  pembrolizumab with the specific chemotherapy agent, 
paclitaxel. The tolerability will be assessed and the anti -tumor activity of two dosing 
schedules will be explored. Biomarkers studies to assess immune effects will also be 
included.  Two schedules will be explored. In Cohort A (phased), two cycles of paclitaxel 
followed by paclitaxel and pembrolizumab with the rationale that giving paclitaxel before 
pembrolizumab, will allow antigen release to occur, provide an initial tumor response, debulk 
the tumor, c hange the tumor’s immune microenvironment, and enhance pembrolizumab’s 
effect. For the exploratory comparison of Cohort B (concurrent), paclitaxel in combination 
with pembrolizumab starting at cycle 1 will be assessed, allowing pembrolizumab to be 
present at the earliest phase of chemotherapy -induced antigen release, and a schedule that is 
consistent with several treatment schedules already reported in ongoing trials with other 
cytotoxic therapy.  
 
2.5.1.  Immunotherapy and Steroids  
Corticosteroids have nonspecific  anti-inflammatory activity and can attenuate 
immunity.31 In general, minimal steroid exposure is preferred when being treated with 
immunotherapy. Corticosteroid premedications are admin istered before paclitaxel to 
decrease the hypersensitivity reactions that can occur, possibly  a reaction to the vehicle 
Cremophor EL, a derivative of castor oil . Grade 2 or higher hypersensitivity reactions 
have been reported to occur at an incidence of less than 3% with weekly paclitaxel at 80 
mg/m2 given as a 1 -hour infusion.32 An 8 to 12 mg dose of I V dexamethasone  pre-
medication given 30  to 60  minutes prior to paclitaxel is a typical dose give n to reduce the 
incidence and severity of reactions.33  
 
Infusion hypersensitivity reactions beyond the second dose are not common.  A 
retrospective study evaluated  449 patients receiving paclitaxel -based chemotherapy for 
the treatment of breast cancer during January 2011 to June 2013. After receiving the first 
two doses of paclitaxel -based chemotherapy without experiencing an infusion 
hypersensitivity reaction, 234 breast cancer patients had their premedications 
discontinued for all remaining paclitaxel doses. These patients tolerated future paclitaxel 
doses without severe or life -threatening complications related to infusion 
hypersensitivity. The majority of patient s did not have any symptoms of an infusion 
reaction, with only two of these patients requiring rescue medication to treat an infusion 
hypersensitivity reaction with subsequent paclitaxel doses (0.85; 95 % confidence 
interval (CI), 0.10 -3.05 %). Discontinua tion of paclitaxel premedications in breast cancer 
patients who have not experienced an infusion hypersensitivity reaction with the first two 
doses of paclitaxel is not associated with increased rate of rescue medication use for 
infusion hypersensitivity.34 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
12 
  
To reduce prolonged corticosteroid exposure in this trial where immunotherapy is being 
combined with paclitaxel, it would be reasonable to taper the steroids after the first cycle 
of chemotherapy. In this trial, dexamethasone 8 mg IV will be given 30 to 60 minutes 
before each paclitaxel administration during cycle 1. If tolerated, dexamethasone should  
then be tapered to 4 mg at Cycle 2 and discontinued at Cycle 3 for subsequent 
infusions.35 In the event of a future infusion reaction, steroid pre -medicati on can be added 
back into the regimen as clinically indicated.  
 
2.6. Study Rationale  
The optimal chemotherapy schedule, dose and timing of combination or sequence with 
pembrolizumab have not been clearly elucidated. Weekly paclitaxel is a mainstay for the 
adjuvant and neoadjuvant treatment of breast cancer.  Combining pembrolizumab with 
paclitaxel in the treatment of HER2 -negative metastatic breast cancer could demonstrate 
synergy and potentiate the effect of chemotherapy by unleashing an anti -tumor immune 
response.  
 
This study will assess the feasibility and safety of phased vs concurrent dosing sequences of 
pembrolizumab with the combination of standard paclitaxel chemotherapy. It is important to 
determine the dosing, safety, and feasibility of giving weekly paclitaxel and pembrolizum ab 
so that future trials may test the activity of this t wo-drug regimen in patients with early -stage 
and/or locally advanced breast cancer.  
 
2.6.1.  Safety Endpoints  
The primary safety objective of this trial is to characterize the safety and tolerability of 
pembrolizumab and paclitaxel (phased vs concurrent) in subjec ts with HER2 -negative 
metastatic breast cancer.  The primary safety analysis will be based on subjects who 
experienced toxicities as defined by CTCAE, Version 4.0 criteria. The attribution to 
study  drug(s), time -of-onset, duration of the event, its resolution, and any concomitant 
medications administered will be recorded.  AEs will be analyzed including but not 
limited to all AEs, SAEs, fatal AEs, and laboratory changes.  
 
2.6.2.  Rationale for Use of irRECIST Criteria  
Immunotherapeutic agents may produce ant itumor effects by potentiating endogenous 
cancer -specific immune responses, which may be functionally anergic prior to treatment. 
The response patterns seen with such an approach may extend beyond the typical time 
course of responses seen with cytotoxic ag ents, and can manifest as a clinical response 
after an initial increase in tumor burden or even the appearance of new lesions (transient 
tumor flare). Thus, standard RECIST criteria may not provide a complete response 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
13 
 assessment of immunotherapeutic agents , such as pembrolizumab.  To address this issue, 
RECIST 1.1 with the adaptation outlined in Table 10, termed irRECIST, will also be used  
after the subject’s first administration of pembrolizumab . 
 
3. PATIENT SELECTION  
 
3.1. Accrual  
A total of 40 evaluable subjects  will be enrolled over an enrollment period of up to 36  
months. The study is planned to enroll approximately  20 evaluable subjects in each  study  
treatment cohort. Evaluable subjects are those who are randomized and begin study therapy.  
Patients will be re cruited through Levine Cancer Institute locations and through referrals. 
Women or men of any race or ethnic origin who meet the study criteria may participate in 
this clinical trial. Children are not included in this clinical trial because the effects of 
pembrolizumab are not known in the pediatric population, but may be eligible for other 
pediatric trials . 
 
3.2. Inclusion Criteria  
Subjects must meet all of the following criteria:  
1. Histologically or cytological confirmed diagnosis of HER2 -negative metastatic breast 
cancer  or locally advanced disease not amenable to resection .  
o Available ER and PR status  from tumor sample with either hormone receptor 
positive or negative tumor(s).  
o For subjects with hormone receptor -positive, HER2 -negative metastatic breast 
cancer, they are eligible if they have already received or been intolerant to at 
least two lines of endocrine therapies  (including the adjuvant and/or metastatic 
setting) , or are appropriate candidates for chemotherapy (i.e. large burden of 
visceral  disease).   
2. Measurable disease by RECIST 1.1, or evaluable bone disease, i.e., bone lesions that 
are lytic or mixed ( i.e. lytic + sclerotic) in the absence of measurable lesion.  Refer to 
section 11 for the evaluation of measurable disease.  
3. Male or female age ≥18 years.   
4. ECOG performance status 0, 1 or 2.  
5. Must have normal organ and marrow function as defined below:  
 
o Hematologic  
▪ Absolute neutrophil count ≥1,500/mcL  
▪ Platelets ≥ 75,000/mcL  
▪ Hemoglobin ≥ 9 g/dL  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
14 
 o Renal  
▪ Creatinine ≤ 1.5X ULN or  
▪ Measured or calculated creatinine clearance (CrCl) ≥ 30 mL/min for 
subject with creatinine levels > 1.5X ULN [CrCl  should be calculated 
per institutional standard; GFR can also be used in place of creatinine 
or CrCl]  
o Hepatic  
▪ Total bilirubin ≤1.5X ULN  or for subjects with total bilirubin levels 
>1.5X ULN, direct bilirubin ≤ULN  
▪ AST(SGOT)/ALT(SGPT) ≤2.5X ULN  
o Coagulation  
▪ PT and PTT ≤ 1.5X ULN ; subjects receiving anticoagulant therapy are 
eligible if PT or PTT is within therapeutic range of intended use of 
anticoagulants  per investigator discretion.  
▪ INR ≤ 1.5; Patients receiving anticoagulant therapy are eligible if their 
INR is stable and within the recommended range for the desired level 
of anticoagulation  per investigator discretion . 
6. Female subjects of childbearing potential must have a negative serum or urine 
pregnancy test within 14 days prior to receiving C1D1 .  
7. Femal e subjects of childbearing potential must be willing to use an adequate method 
of birth control as outlined in Section 8.1.10, be surgically sterile, or abstain from 
heterosexual activity for the course of the study and 120 days after the last dose of 
study therapy .  Subjects  of childbearing potential are those who have not been 
surgically sterilized or have not been free from menses for > 1 year. Male subjects of 
reproductive potential should agree to use an adequate method of contraception 
starting with t he first dose of study therapy and 120 days after the last dose of study 
therapy. Abstinence is acceptable if this is the established and preferred contraception 
for the subject.  
8. Has completed the screening requir emen t of a core or punch biopsy of a tumor lesion  
per Section 5  (bone tissue not acceptable) . Biopsy of the breast tumor or other 
regional areas is acceptable  (i.e. lymph nodes, skin lesions) .  
o Subjects who are unable to meet the screening requirement of a tumor biopsy 
due to inaccessible tumor , subject safety concern , or bone -only disease  may 
submit an archived tumor specimen from primary tumor or metastatic biopsy  
collected within 12 months from consent .  
o Subjects who decline  tumor biopsy may submit archived tumor specimen  as 
specified above  (within 12 months from consent ) only after Sponsor -
Investigator approval.  
9. Ability to understand and the willingness to sign the written informed consent 
document . 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
15 
  
3.3. Exclusion Criteria  
Subje cts must not meet any of the following criteria:  
1. Prior chemotherapy within 3 weeks, prior targeted small molecule therapy or 
radiation therapy within 2 weeks, or prior anti -cancer monoclonal antibody 
(mAb) for direct anti -neoplastic treatment within 4 week s prior to Cycle 1  Day 1.  
2. Not recovered (i.e., ≤ Grade 1) from adverse events due to agents previously 
administered.  
o Note: Subjects with ≤ Grade 2 neuropathy or alopecia of any grade 
are an exception and may qualify for the study.  
3. More than three prior lines of chemotherapy for HER2 -negative  metastatic  
disease  or for locally advanced  disease  that is not amenable to resection .  
o Note: Non -Chemotherapy regimens do not count as prior lines (ex: 
hormonals, biologics)  
4. Has received prior t herapy with an anti -PD-1, anti -PD-L1, anti -PD-L2 agent or 
with an agent directed to another co -inhibitory T -cell receptor (e.g. CTLA -4, 
OX-40, CD137)  or has participated in Merck MK -3475 trial(s)  and received MK -
3475 as part of protocol therapy . 
5. Has a diag nosis of immunodeficiency  or is receiving systemic steroid therapy or 
any other form of immunosuppressive t herapy within 7 days prior to Cycle 1 Day 
1 
6. Has had major surgery within 3 weeks prior to Cycle 1  Day 1.  
7. Has received any other investigational agent s within 4 weeks of Cycle 1 Day 1 of 
study therapy.  
8. Known active uncontrolled or symptomatic central nervous system (CNS) 
metastases and/or  carcinomatous meningitis as indicated by clinical symptoms, 
cerebral ed ema, and/or progressive growth .  
o Note: Subjects with treated CNS metastases are eligible if they are 
asymptomatic, have no requirement for steroids, no requirement for 
anticonvulsants,  and stable CNS radiographic study showing no significant 
vasogenic edema ≥ 4 weeks since completion of radiation and ≥ 2 weeks since 
discontinuation of steroids.  
9. History of known all ergic reaction to paclitaxel   
10. Has a history or current evidence of any co ndition, therapy, or laboratory 
abnormality that might interfere with the subject’s participation for the full 
duration of the trial, or is not in the best interest of the subject to participate, in 
the opinion of the treating investigator.  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
16 
 11. Is pregnant or breastfeeding, or expecting to conceive or father children within 
the projected duration of the trial, starting with the screening visit through 120 
days after the last dose of study  treatment. Pregnant women are excluded from 
this study because pacli taxel is an agent with the potential for teratogenic or 
abortifacient effects.  Because there is an unknown but potential risk for adverse 
events in nursing infants secondary to treatment of the mother with paclitaxel, 
breastfeeding should be discontinued if the mother is treated with paclitaxel.  
These potential risks also apply to pembrolizumab being used in this study.  
12. Has a known history of Human Immunodeficiency Virus (HIV) or known 
acquired immunodeficiency disorder (AIDS). HIV -positive patients on 
combination antiretroviral therapy are ineligible because of the potential for 
pharmacokinetic interactions with paclitaxel and pembrolizumab.  In addition, 
these patients are at increased risk of lethal infections when treated with marrow -
suppressive therap y.  
13. Has known active infection with hepatitis B or hepatitis C.  
14. Has an active autoimmune disease that has required systemic treatment in past 2 
years (i.e. with use of disease modifying agents, corticosteroids or 
immunosuppressive drugs).   
o Replacement the rapy (i.e., thyroxine, insulin, or physiologic corticosteroid 
replacement therapy for adrenal or pituitary insufficiency, etc.) is not 
considered a form of systemic treatment.  
15. Has a known additional malignancy that progressed or required active treatment 
within the last 5 years.  
o Note: Exceptions include basal cell carcinoma of the skin, squamous cell 
carcinoma of the skin that has undergone potentially curative therapy, or 
in situ cervical cancer.  
16. Has a history of (non-infectious) pneumonitis that required  steroids  or current 
pneumonitis . 
17. Has an active infection requiring systemic therapy.  
18. Has known psychiatric or substance abuse disorders that would interfere with 
cooperation with the requirements of the trial.  
19. Has received a live vaccine within 30  days of Cycle 1 Day 1 of study therapy.  
o Note:  Seasonal influenza vaccines for injection are generally inactivated 
flu vaccines and are allowed; however,  intranasal influenza vaccines (e.g., 
Flu-Mist®) are live attenuated vaccines, and are not allowed . 
 
4. INVESTIGATIONAL PLAN  
 
4.1. Milestone Dat e Definitions  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
17 
 Eligibility date:  the date of the last documented criterion that confirmed subject 
eligibility.  
Enrollmen t date:  the date subject is randomized to one of the  study  treatment arms.  
Treatment discontinuation date: Date investigator decide s to discontinue subject from 
study  treatment .  
• For subjects who have  received pembrolizumab study treatment, this date 
is the date the investigator decides to discontinue subject from 
pembrolizumab.  
• For subjects in cohort A who have not  yet received pembrolizumab, this 
date is the date the investigator decides to discontinue subject from 
paclitaxel.  
 
4.2. Overall Study Design  
This is a n open -label, randomized pilot study designed to evaluate the safety and 
feasibility of the following two regimens: Cohort A) phased regimen of pembrolizumab 
in which paclitaxel is followed by paclitaxel plus pembrolizumab and Cohort B) 
concurrent regimen of paclitaxel plus pembrolizumab. Following informed consent and 
eligibility check, subjects  will be randomized to either Cohort A or Cohort B.  
 
Data from this study will be collected on electronic case report forms (eCRFs) and 
stored in the CTMS.  
 
4.3. Randomization/ Registration /Enrollment  
Following informed consent and eligibility check per standard  operating procedures, 
subjects will be randomized in a 1:1 fashion to either Cohort A (phased) or the Cohort B 
(concurrent) and assigned a Study ID number. This will be accomplished utilizing the 
CTMS whereby a list of Study IDs and associated  study  treatment arm assignments 
randomly generated prior to study activation will be uploaded by a member of the Levine 
Cancer Institute Biostatistics Core. The Study ID will be a four digit randomly generated 
ID number, ranging from 0001 to 9999. A stratified block randomization will be utilized 
including hormone receptor status (positive versus negative) to reduce confounding of 
comparisons between the  study  treatment arms.  
 
4.4. Pre-Treatment  
4.4.1.  Informed Consent  
No protocol -related assessments may be performed prior to obt aining informed consent. 
Baseline assessments will be conducted according to the Study Calendar.   The 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
18 
 investigator or qualified designee must obtain documented consent from each potential 
subject prior to participating in a clinical trial  per standard oper ating procedures .  
 
4.4.2.  Medical History  
Demographic information , medical history and baseline conditions will be obtained by 
the investigator or qualified designee.  Medical history will include all active conditions, 
and any condition diagnosed within the pri or 10 years that are considered to be clinically 
significant by the Investigator. Details regarding the subject’s MBC  will be recorded 
separately and not listed as medical history.   
 
4.4.3.  Prior and Concomitant Medications  
All medication that is considered necessary for the subject’s welfare, and which is not 
expected to interfere with the evaluation of the study treatment, may be given at the 
discretion of the Investigator. All medications taken  from the time of informed consent  
and during study treatment will be recorded in the medical record per standard clinical 
practice.  
 
4.4.4.  Prior Treatment Details for Breast Cancer  
The investigator or qualified designee will review and record all prior cancer treatments 
including systemic treatments, radiation and surgeries.  If applicable, d ocumentation of 
clinical and/or radiographic disease progression on the most recent therapy wi ll be 
collected.   
 
4.4.5.  Baseline Procedures  
Physical exam, ECOG performance status, vital signs, clinical laboratory tests , baseline 
adverse event assessment , and ECG  should be performed during screening within the 
timeframe defined in Section 5.  
 
  
 
4.4.5.1.  Radiolog y and Tumor Measurements  
Imaging tests, including CT scan of chest, abdomen, and pelvis with contrast or MRI 
aimed at defining the extent of existing disease must be performed and documented 
within the timeframe defined in Section 5 . A bone scan  will be do ne at Baseline within 
the timeframe defined in Section 5  to document presence or absence of bone metastasis.  
  
4.4.6.  Correlatives  
4.4.6.1.  Tissue Biopsies  
It will be mandatory to obtain a tissue biopsy during screening before study treatment  
initiation in all subjects  and then within 5 days prior to study treatment on Cycle 3, 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
19 
 Day 1. Bone tissue is not acceptable  for research biopsies . See Section 3.2 (Inclusion 
#8) for possible exceptions to tumor biopsy. Optional time points include within 5 
days prior to study treatment on Cycle 5, Day 1 and  within 21 days following 
documented disease progression . Subsequent b iopsies ideally will be obtained from 
the same site used at Baseline, but this is not a requirement . Research biopsies may be 
obtained even if the subje ct has discontinued study treatment.  
 
An effort should be made to ask subjects  in Cohort A if they can undergo the biopsy 
prior to  study  treatment on Cycle 5 Day 1 as this would be after 2 cycles of paclitaxel 
combined with pembrolizumab, and this would provide important information 
regarding PD -L1 expression and effect on TILs in the tumor after combined 
chemotherapy and immunotherapy. The overall goal of the trial would be to obtain 
paired pre -treatment and on -treatment tumor biopsy in at least 10 subjects  in each 
cohort.  
Biopsies will be obtained only if they ca n be performed under local anesthesia. 
General anesthesia will not be used to obtain biopsies that are to be used only for 
research purposes. Biopsies may be obtained with the assistance of either a surgical 
consultant  or designee, a dermatological consult ant or designee,  or a member of the 
interventional radiology staff.  
 
Biopsies performed for research purposes will only be obtained after the procedure 
has been explained to the subject , and per institution policy, the clinic specific 
informed consent has  been secured. Subjects  will have the opportunity to consent or 
refuse the use of their tumor samples  to be banked at the CHS BioSpecimen 
Repository  for additional unplanned  future  studies.  
 
4.4.6.2.  Archived Tumor Tissue  
Tumor tissue samples  will be collected  (if available)  for each subject  on-study to 
evaluate the expression  of, but not limited to, PD -L1 and TILs. This includes the 
following:  
 
1) Sample of  tissue from time of original diagnosis (breast cancer primary)  
2)  Sample of tissue from initial metastatic d iagnosis (any site of metastases)  
 
Subjects will have the opportunity to  sign the consent form  or refuse the use of  any 
archival specimens collected  to be banked at the Atrium Health  BioSpecimen 
Repository for any desired unplanned future analyses.  
 
4.4.6.3.  PD-L1 Expression in Tumor  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
20 
 Recent data suggest s that inducible PD -L1 expression may be important for responses 
to PD -1 blockade therapy.  PD -L1 is expressed in about 20% of TNBCs in tumor 
samples from constructed tissue microarrays.36  In hormone  receptor -positive breast 
cancer, PD -L1 expression has been reported at 6%, a smaller incidence compared to 
TNBC, while still suggestive that checkpoint inhibitors may have a role in luminal 
breast cancer.37   
 
An archived sample or core  or punch  biopsy (fine needle aspirate not adequate) 
collected during screenin g should  be submitted to the CHS BioSpecimen Repository  
for characterization of PD -L1 expression  if it can be safely obtained .  Tumor tissue 
collected during screening should be submitted in formalin or as formalin -fixed 
paraffin embedded tumor tissue blocks (preferred).   
  
Additionally, if available, archived tumor tissue specimens from prior biopsies will be 
collected for determination of PD -L1 tumor status to compare biomarker expressio n 
in archived specimens against the newly obtained tumor tissue that is collected as a 
requirement for entry into the trial.  Tumor tissue collected may also be used to 
support analysis of additional exploratory biomarkers. Details regarding time points 
for collection of tumor tissue are outlined in the Study Calendar  (Section 5) . 
 
4.4.6.4.  Tissue Infiltrating Lymphocytes (TILs) in Tumor  
TILs have been shown to provide prognostic and predictive value, particularly in 
TNBC.38,39 H&E -stained slides will be evaluated for TILs according to standardized 
methodology described by Salgado et al.40  Additionally, there is recent data 
suggesti ve that the subset of breast cancer  tumors  with the highest potential to benefit 
from checkpoint inhibitors may be those breast tumors that have both high TILs and 
high PD -L1 expression.41 
 
4.4.6.5.  Genomic Analysis  
The application of new technologies such as next generation sequencing has provided 
the opportunity to define certain tumor types at the genetic level as being 
“hypermutated.” It is possibl e that the hypermutated states may be correlated with 
response to pembrolizumab in HER2 -negative breast cancer. Recent data in a group 
of patients with progressive metastatic carcinoma , with or without mismatch repair 
deficiency and treated with pembrolizu mab, showed that mismatch -repair st atus 
predicted clinical benefit with pembrolizumab42.  
 
If tissue not previously sent for genomic analysis, FFPE tumor will be sent for 
genomic analysis by next -generation sequencing panel (≥400 genes). At least 50 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
21 
 mm2, or the equivalent of 4  core biopsies using an 18 gauge needle,  is required for 
testing.  
 
 
4.4.6.6.  Patient -Derived Xenografts  (PDX) Models  
Cancer research and drug development have historically relied upon the use of in 
vitro cell lines and in vivo models such as genetically -engineered mice and cell line -
injected mice (i.e., cell line xenografts).  These models lack critical elements such as 
tumor heterogeneity and its associated microenvironment and therefore do not 
provide an accurate representation of a patient’s tumor.   
 
PDX models have been established by implanting a fragment of a patient’s fresh 
tumor tissue into immune -deficient mice.   Tumors are allowed to engraft and grow 
before they are resected and subsequently implanted into a second generation of mice.  
Once growth is observed in the second generation of mice, the PDX model is 
considered successfully established and can be mainta ined and passaged into 
subsequent generations of mice or cryopreserved for future use.  Extensive 
characterization of PDX models with regard to histopathology, gene expression and 
genomic sequence has shown high fidelity of the molecular characteristics of  the 
original patient tumor. Therefore, these models have a distinct advantage over other 
models and have become an important in vivo model for oncology research and drug 
development.   
 
The use of PDX models as a robust research platform for optimizing on cology drug 
development efforts has been well recognized; however, until recently data was 
lacking to support the accuracy of these models to predict clinical response.  
Champions Oncology and many academic researchers have data sets that highlight 
the hig h degree of accuracy of personalized PDX models in predicting response of 
individual patients across a variety of tumor types.  
 
For this study, the objective is to collect tumor tissue in metastatic triple -negative 
breast cancer subjects  to create patient -derived xenograft mouse models for 
translational research purposes.  This will give potential insight to mechanisms of 
response and resistance, pre - and post -treatment, with this combination regimen.    
 
Fresh tumor tissue will be obtained through a biopsy  during screening . To maximize 
the success of tumor engraftment in the immune -deficient mouse, it is requested that 
approximately 0.5 cm3 or a minimum of 3 core biopsies using an  18 gauge needle (or 
equivalent) be obtained.  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
22 
 Freshly acquired specimens will  be placed into one to two 50 -ml vials containing 
transport medium that will be provided by Champions and labeled with a unique 
subject number identifier.   Vials containing the tissue specimen will be packaged in 
an insulated container with coolant blocks .  Transportation of the specimen to the 
designated implantation site will be arranged in advance with Champions Clinical 
Operations Staff. Ideally, the time from tumor extraction to placement in media 
should be immediately but can be up to 30 minutes. Exa ct times will be recorded.  
 
A whole blood sample will also be collected and submitted at the time of tumor 
biopsy to Champions Oncology.  This will enable a comparison of normal DNA 
profile to tumor DNA for PDX genomic analysis.  Lavender -topped, EDTA -
containing tubes will be used for collection.  Once collected, whole blood samples 
will be included with tissue specimen collection in an insulated container for transport 
to the designated implantation site.  Exact collection times will be recorded.  
 
Upon re ceipt of the tumor specimen at the designated implantation site, tumor tissue 
will be implanted  into immune -deficient mice following the standard operating 
procedures (SOPs). Evaluation for tumor growth will occur as follows: tumor 
dimensions will measured  twice weekly by digital caliper and data, including 
individual and mean estimated tumor volumes are recorded for each group. Tumor 
volume will be calculated using the formula: TV= width2 x length x π/2.  
Monthly reports of tumor growth status will be provided by Champions to the PI and 
designated individuals.  
 
Genomic sequencing (whole exome and RNA sequence) will be performed by 
Champions (or it’s designate) on successfully generated PDX models and provided to 
the Sponsor -Investigator for research pur poses.   
 
4.4.6.7.  Correlative Studies in the Tissue  
A priority ranking of studies on tumor tissue samples are listed below  
1) PD-L1 
2) TILS  
3) Genomic analysis  
4) Patient -derived xenografts for metastatic triple -negative breast cancer subjects  
only 
Tissue does not need to be sent for genomic analysis if already performed on 
previously collected tissue.  
Other exploratory biomarkers may also be measured in the tissue s. 
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
23 
 4.4.6.8.  Blood Correlatives  
4.4.6.8.1.  Circulating Tumor DN A 
Circulating tumor DNA (ctDNA) could serve as an early biomarker of therapeutic 
response to checkpoint inhibitors.43  Blood (20 ml; 2 BCT or equivalent tubes) 
will be drawn from the subject  and submitted for isolation of ctDNA and analysis 
by next generat ion sequencing methods by a panel (≥40 genes).  This will be 
collected pre -treatment  and at the timepoints as defined in Section 5.  
 
4.4.6.8.2.  BRCA Mutations  
A phase II study identified the first genomic marker —mismatch repair 
deficiency —to predict clinical benefit of immune checkpoint blockade with the 
anti–PD-1 antibody pembrolizumab. Among 28 patients with colorectal cancer, 
40% of the 10 patients with mismatch repair –deficient tumors responded to 
pembrolizumab, but no responses were seen among the 18 mism atch repair –
proficient patients. The difference in disease control rates (response plus stable 
disease) was even greater: 90% in the mismatch repair –deficient group and only 
11% in the mismatch repair –proficient group.42 Mismatch repair deficiency leads 
to an accumulation of genetic mutations in a tumor. It is hypothesized that 
immune checkpoint inhibitors would work particularly well against mismatch 
repair -deficient tumors. For breast cancer subjects , the determin ation of  BRCA 
status will be recommended, if they have not had germline testing performed.  
 
4.4.6.8.3.  Biomarkers in the Blood  
A pre-treatment  blood sample will be collected with additional blood collected at 
subsequent time points according to the study calendar  in Section 5 , using one 
serum separator tube (SST) and two cell preparation tubes (CPT) for blood cells 
separation and storage.  Samples will be delivered to the CHS Bio Specimen 
Repository to be processed and stored for batch analysis at the end of the study. 
The anal ysis will include but no t be limited to immunotyping and cytokine 
profiling in Dr. David Foureau’s LCI Immune Monitoring Core Laboratory.  
 
4.4.6.8.4.  Optional and Future Studies  
All study participants will be invited to provide blood sample s for future 
unplanned stud ies.  Participation will be optional for all subjects  entering the 
study. A subject ’s acceptance of unplanned future analyses will not be a 
requirement of their participation in the main study.  Subjects will have the 
opportunity to consent or refuse the collection of these samples for additional 
unplanned studies. If the subject agrees to this collection, t wo 10 ml tubes of 
blood will be collected  pre-treatment  and other timepoints  as defined in Section 5 , 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
24 
 one red top (for serum) and a heparinized green to p (for plasma) and frozen at -70̊ 
C to -80̊ C and stored in the CHS Bio Specimen Repository for future research.  
 
 
 
4.5. Treatment  
4.5.1.  Adverse Event (AE) Monitoring  
The investigator or qualified designee will assess each subject to evaluate for any new or 
worsening AEs as specified in the Study Calendar and more frequently if clinically 
indicated.  Adverse events will be graded and recorded throughout the study from  
randomization  through  30 days after last administration of study  treatment , using  
CTCAE Version 4.0.  Toxicities will be characterized by seriousness, causality, toxicity 
grading, and action taken with regard to study  treatment  and recorded in the CTMS .   
 
4.5.2.  Vital Signs  
The investigator or qualified d esignee will take vital signs  prior to the administration of 
each dose of study  treatment as specified in the Study Calendar.  Vital signs include 
temperature, pulse, respiratory rate, and blood pressure.   
 
4.5.3.  ECOG PS  
The investigator or qualified designee will assess ECOG status at  the timepoints  
specified in the Study Calendar  in Section 5 . 
 
4.5.4.  Physical Exam  
The investigator or qualified designee will perform a complete physical exam including 
weight  at the timepoints  specified in the Study Calendar  in Section 5 . New clinical ly 
significant abnormal findings should be recorded as AEs.  Height will be measured at 
screening only.   
 
4.5.5.  Laboratory Procedures and Assessments  
Laboratory tests for hematology and chemistry at the timepoints  specified in the Study 
Calendar  in Section 5 . 
Resu lts must be reviewed by the investigator or qualified designee and found to be 
acceptable prior to each dose of study  treatment.  
 
4.5.6.  On Study Tumor Imaging  and Assessment of Disease  
Post treatment tumor imaging assessment s should be performed at the time points 
specified in the Study Calendar in Section 5 .  The same modality used at screening 
should be used at all follow -up imaging assessments.  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
25 
  
If no bone lesions were identified at Baseline, bone scans will only be repeated as 
clinically indicated (i.e . showing signs or symptoms of new or progressing bone 
metastases). Subjects with bone metastasis present at Baseline will have bone scans at 
the same time point as study tumor imaging (CT/MRI), based on how long subjects  have 
been on study as defined in S ection 5 .  
 
Imaging should follow calendar days and not be delayed for any dose interruptions that 
may occur. Imaging should continue to be performed until disease progression, the start 
of new anticancer treatment, withdrawal of consent  for study participation , death, or 
notification by the  Sponsor -Investigator , whichever occurs first.   
 
 
Radiographic d isease progression must  be confirmed at least 4 weeks after the first 
tumor imaging indicating progressive disease in clinically stable subjects.  Subjects in 
Cohort A will not require confirmatory imaging if radiographic disease progression is 
identified at the first follow -up imaging time -point (prior to pembrolizumab). 
Pembrolizumab -treated s ubjects who have unconfirmed radiographic disease progression 
may continue on treatment until progression is confirmed (or possibly even later) 
provided they have met the conditions detailed in irRECIST ( Table 10). 
 
For s ubjects with new symptoms of osseous metastasis [e.g., new bone pain and/or new 
persistently elevated alkaline phosphatase (AP)] a bone scan should be obtained.   
 
4.6. End of Treatment  
An end of treatment visit should be completed after study treatment is discontinued.  End 
of treatment visit is  outlined in the Study Calendar.   
 
Subjects will be tracked for at least 30 days following cessation of study treatment to 
monitor for adverse events and any other unanticipated problems. If the end of treatment 
visit occurs prior to 31 days from last dos e, subjects will be contacted by telephone on 
day 31 or next business day for monitoring. Subjects will be followed until all treatment -
related toxicities have resolved, returned to baseline, stabilized, or are deemed 
irreversible according to standard of care.   
 
Note: In the event a subject is discontinued from pembrolizumab, but  is experiencing 
benefit (in the investigator’s opinion) from the paclitaxel, continuation of paclitaxel will 
not be considered protocol -directed therapy or start of new or subsequent anticancer 
therapy.  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
26 
  
4.7. Follow -Up 
Subjects will be contacted approximately  every 6 months from t reatment discontinuation 
date, until death , lost to follow -up, or until the criteria defined for the final analysis 
(Section 12.4.1 ) are reached.  However, in the event the criteria for the final analysis are 
met, and there are subject s who have not yet been discontinued from study treatment, 
subjects in follow up will continue to be followed until all subjects have discontinued 
study treatment (see Section 6.6) and completed the required 30 day safety monitoring 
period (see Section 4.5.1).  Subjects will be contacted by telephone , in writing, or during 
clinic visits after treatment discontinuation for collection of follow -up information . 
Follow -up clinical information may also be obtained through chart reviews.  Death 
information from p ublic sources i.e. death registry, obituary listing, etc. can also be used 
when available and verifiable.  
 
4.8. Subject Withdrawal  and Off Study  
Subjects may withdraw consent at any time for any reason or be removed from the trial 
at the discretion of the investigator should any untoward effect occur.   
 
In this trial, a subject may discontinue from study treatment but continue to participate in 
the regularly scheduled activities, as long as the subject does not withd raw consent  for 
participation . 
 
A subject will  be discontinued from the trial for any of the following reasons:  
• The subject withdraws consent  for participation on the study  
• The subject is lost to follow -up 
• Investigator’s decision to withdraw the subject from study , which may 
include noncompliance with study treatment or procedure requirements   
• Subject death  
 
In all cases, the reason for withdrawal and/or subject going Off Study must be 
documented in the subject’s medical records and/or research record and recorded  in the 
eCRF . 
 
4.9. Screen Failures/Subject Replacements  
A subject who, for any reason (i.e. failure to satisfy the eligibility criteria or withdraws 
consent), terminates their participation in the study before being randomized is regarded 
as a “screen failure.”  
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
27 
 A subject who discontinues from the trial after randomization will not be replaced.  
 
 
5. STUDY CALENDAR  
The following tests and evaluations will be performed according to the schedule below. Baseline 
(i.e., pre -study) evaluations must be performed within 14 days prior to Cycle 1 Day 1 , unless 
otherwise indicated in one of the footnotes below the table.  All imaging must be performed 
withi n 28 days prior to Cycle 1 Day 1 .  A cycle is defined as an interval of 21 (+/- 3) days.  
Evaluation   Pre-
Study  Cycle 1  
Day 1  
(C1D1)  C1D81 C2D1  C2D81 C3D1  C3D81 C4 
and 
after; 
D1 C4 
and 
after; 
D81 Every 
6 
weeks  
(+/- 7 
days)  End of 
Treatment 
(w/in 31 
days of 
last dose)  Progression  
Follow 
Up21 
Informed 
consent  X5             
• History23 
• weight / 
height3  
• physical 
exam  
• ECOG PS  X X2  X4  X4  X4   
X  
 
Vital signs24  X X2 X X X X X X X  X   
Serum or 
urine 
pregnancy 
test in 
WOCBP  X    
      
   
CBC with 
differential, 
platelets  X X2 X7 X6 X7 X6 X7 X6 X7  
X  
 
PT/PTT/  
INR X             
Serum 
chemistries 
and LFTs8 X X2  X6  X6  X6   
X  
 
Thyroid 
function 
tests (TSH 
and free T4)  X       X9   
  
 
ECG  X             
Paclitaxel10  X X X X X X X X     
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
28 
 1. Day 8 visits are not applicable for subjects receiving pembrolizumab monotherapy.  Day 8 paclitaxel treatment may 
have a + 2 day window (it may be given up to 2 days later than Day 8) but paclitaxel doses should not be 
administered  any closer than 7 days apart.  
2. Physical exam, ECOG performance status, weight, vital signs, and clinical laboratory tests do not need to be 
repeated prior to Cycle 1 Day 1  unless the subject’s  condition is deteriorating.  
3. Collect height at Screening  only. 
4. Physical exam, weight, and ECOG PS within 7 days of Day 1 for Cycles 2 and beyond.  
5. Within 28 days prior to study treatment initiation ). 
6. May be performed within 72 hours  
7. May be performed within  1 day on Day 8 for Cycle 1 and beyond . 
8. Includes : sodium, potassium, bicarbonate, chloride, glucose, BUN, creatinine, calcium, total protein, and albumin, 
alkaline phosphatase, total bilirubin, AST and ALT.   
9. Blood draws for thyroid function tests should be repeated every 4 cycles  starting at Cycle 5 Day  1 (within 72 
hours) . Pembro -
lizumab   X11  X11  X  X      
Tumor 
biopsy, if 
accessible  X19     X20  X12   
 X12  
Evaluation  
continued  
 Pre-
Study  Cycle 1  
Day 1  
(C1D1)  C1D81 C2D1  C2D81 C3D1  C3D81 C4 
and 
after; 
D1 C4 
and 
after; 
D81 Every 
6 
weeks  End of 
Treatment 
(w/in 31 
days of 
last dose)  Progression  
Follow 
Up21 
Archived 
tumor tissue  X             
Blood for 
circulating 
tumor DNA    X    X  X13   
  
 
Optional 
Future 
research 
blood draw  X    X  X14   
 X14  
Blood for 
biomarkers    X  X  X  X15      
Blood for 
BRCA 
mutation16 X          
  
 
Imaging 
studies 
and/or tumor 
assessments  X5         X17,18   
 
Review 
adverse 
events25 X X X X X X X X X  
X  
 
Survival 
status              X22 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
29 
 10. If paclitaxel needs to be omitted for the subject due to a paclitaxel -related toxicity or the subjec t has received 
maximum benefit from paclitaxel as deemed by the treating physician and the Sponsor -Investigator,  paclitaxel may 
be discontinued.  
11. ONLY subjects randomized to Cohort B will receive pembrolizumab on Cycle 1 Day 1 and Cycle 2 Day 1 before 
paclitaxel. 
12. Optional within 5 days of C5D1 (strongly encouraged for subjects in Cohort A) . If subject discontinues treatment  
due to disease progression , a biop sy will be performed   within 21 days of confirmed progression.  If subject has 
confirmed disease progression but remains on treatment, a biopsy will not be performed.   
13. This will be collected at pre -treatment and then within 72 hours prior to Day 1 of every 2 (odd-numbered) cycles  
starting with Cycle 3 .  
14. Within 72 hour s of C5D1and within 21 days of confirmed progression. 
15. Within 72 hours of C4D1only. 
16. If applicable as determined by the treating investigator and not previously obtained, can be drawn at any time while 
on study in conjunction with genetic consultation.  
17. The first follow -up imaging timepoint should be 6 weeks (+/ - 7 days) from C1D1 . Subse quent fo llow-up imaging 
frequency as referenced in the calendar and below (based on length of time the subject has been on the study) 
should be based on the timepoint of  the previous scan , not C1D1 . If a subject  has been on study for ≥ 6 months, the 
treating physician may decide to lengthen the interval to every 9 weeks (63 days ± 7 days)  from previous scan , or 
more frequently, if clinically indicated. The las t scan performed at the 6 week internal must occur on or after the 6 
month on study date; subsequent scans can be scheduled at the 9 week interval. The last scan performed at the 9 
week interval must occur on or after the 12 month on study date; subsequent  scans can be scheduled at the 12 week 
interval.  After 12 months, imaging frequency can be reduced to every 12 weeks (84 ± 7 days)  from previous scan , 
or more frequently if clinically indicated.   
18. Imaging should follow calendar days and not be delayed for any dose interruptions that may occur  until 
progression . 
19. May be collected anytime during screening prior to study treatment initiation . Subjects for whom tumor biopsies 
cannot be obtained during screening due to  inaccessible tumor or subject sa fety concern may submit an archived 
tumor specimen from primary tumor or metastatic biopsy collected within 12 months from consent.  Bone tissue is 
not acceptable for research biops ies. 
20. Within 5 days of C3D1  
21. Subjects will be contacted approximately every 6 months from treatment discontinuation date, until death, lost to 
follow -up, or until the criteria defined for the final analysis (Section 12.4.1) are reached .   
22. For surviving subjects who receive subsequent anti -cancer therapy prior to documented disease p rogression, collect 
start date of first subsequent anti -cancer therapy.  In the event a subject is discontinued from pembrolizumab, but is 
experiencing benefit from the paclitaxel, continuation of paclitaxel will not be considered protocol -directed therapy 
or start of new or subsequent anticancer therapy.  
23. To include baseline conditions  present at the time of study treatment initiation  
24. VS to include temperature, pulse, respiratory rate, and blood pressure  
25.  Adverse event s will be foll owed for 30 days a fter last administration of study treatment . 
 
6. TREATMENT PLAN  
 
6.1. Drug Dosage and Administration  
6.1.1.  General Considerations  
Trial treatment should begin on the day of or within 72 hours of randomization. 
Study treatment should be administered after all procedures/assessments have been 
completed as detailed in the Study Calendar.  A cycle is defined as an interval of 21 
(+/- 3) days (delays due to holidays, weekends and bad weather will be pe rmitted 
and will not be counted as a protocol deviation ). No investigational or commercial 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
30 
 agents or therapies intended to treat the subject ’s malignancy may be administered 
while the subject is receiving study therapy, other than those described below.  
 
6.2. Paclitaxel  
Subjects  will receive paclitaxel  80 mg/m2 as an IV infusion over 60 minutes on 
Days 1  and 8  every 21 days. However, given the variability of infusion pumps from 
site to site, a window of -5 minutes and +10 minutes is permitted.  In the event of a 
dosing delay, a make -up dose of paclitaxel may be given as outlined in Section 7.2 . 
A window of +/ - 3 days is allowed for the Day 1 dose and a + 2 day window is 
allowed for the Day 8 dose (it may be given up to 2 days later than Day 8) bu t 
paclitaxel doses should not be administered any closer than 7 days apart.  
Paclitaxel is commercially available. Anaphylaxis precautions should be observed 
during administration.  
Premedications for possible hypersensitivity reactions involving paclitaxel and/or 
its components will be given approximately 30 to 60 minutes prior to paclitaxel.  
The following is suggested:  
• Dexamethasone 8 mg IV (or equivalent) * 
• Diphenhydramine 25 mg IV (or equivalent)  
• Famotidine 20 mg IV (or equivalent)  
*A suggested regimen to  taper dexamethasone is the following: dexamethasone 8 
mg IV 30 to 60 minutes prior to each paclitaxel infusion during cycle 1 and then 
dexamethasone 4 mg IV 30  to 60  minutes prior to each paclitaxel infusion during 
cycle 2, and then discontinued for subse quent infusions, if tolerated.  
The dose of paclitaxel will be calculated each cycle using the subject ’s most recent 
weight during  screening  (baseline weight) . If the subject’s weight changes >10% 
from baseline weight, recalculate that total dose  per standard clinical practice .  
 
6.2.1.  Treatment Criteria  
On Cycle 1 Day 8  and beyond , paclitaxel  can be administered provided that the 
subject  meets the following criteria:  
• ANC ≥ 1,000/l 
• Platelets ≥ 75,000/l 
 
If paclitaxel  is held, follow guidelines for dosing pembrolizumab. It is possible for 
subjects  to continue on pembrolizumab even if paclitaxel  is held, when  appropriate.  
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
31 
 6.3. Pembrolizumab  
Subjects  will receive 200 mg pembrolizumab as  an IV infusion over 30 minutes  on Day 1             
of every 21 days (+/ - 3 days) .  
 
Sites should make every effort to target infusion timing to be as close to 30 minutes as 
possible.  However, given the variability of infusion pumps from site to site, a w indow of 
-5 minutes and +10 minutes is permitted . 
 
A sterile, non -pyrogenic, low -protein binding 0.2 to 5 µm in -line filter made of 
polyethersulfone (PES) must be used during administration of pembrolizumab to remove 
any adventitious particles.  If the inf usion set does not contain 0.2 to 5 µm in -line filter, it 
is recommended to use 0.2 to 5 µm add -on filter which may contain an extension line 
(Note: the materials of the extension line and filter should be as mentioned above).  
 
Pembrolizumab 100 mg/ 4mL so lution for injection  will be supplied by Merck.  
 
The investigator shall take responsibility for and shall take all steps to maintain 
appropriate records and ensure appropriate supply, storage, handling, distribution and 
usage of study  treatments in accordance with the protocol and any applicable law s and 
regulations.  
 
6.4. Treatment Administration  
6.4.1.  Cohort A, Phased Pembrolizumab  
For subjects  randomized to Cohort A, paclitaxel will be administered per Section 
6.2 during Cycles 1 and 2. No pembrolizumab will be given during Cycles 1 and 2. 
Starting with cycle 3 and subsequent cycles, pembrolizumab will be administered 
per Section 6.3  before  paclitaxel  on day 1 every cycle . 
 
6.4.2.  Cohort B, Concurrent Pembrolizumab  
For subjects  randomized to Cohort B, pembrolizumab will be administered per 
Section 6.3  on day 1 before  paclitaxel  every cycle .  Paclitaxel will be administered 
per Section 6.2 , on days 1 and 8 every cycle .  
 
6.4.3.  Pembrolizumab Monotherapy  
If paclitaxel needs to be o mitted for the subject due to a paclitaxel -related toxicity  
(e.g., subject develops a hypersensitivity reaction o r grade 3 or grade 4 neuropathy),  
the subject  may be allowed to continue on protocol with single -agent 
pembrolizumab.   
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
32 
 If the  subject has rec eived maximum benefit from paclitaxel as deemed by the 
treating physician , and in consultation with the Sponsor -Investigator, which could 
include a situation of complete response, partial response, or stable disease ≥ 6 
months, paclitaxel can be discontinu ed, and treatment with pembrolizumab alone 
may be continued.  Safety asse ssments, including  physical exam, vital signs, 
laboratory assessments, and monitoring for the occurrence of adverse events will be 
performed according to Section 5 .  The dosing of pembrolizumab will be given 
once every 3 weeks as described above.  
 
 
6.4.4.  Table 1: Trial Treatment  
Regimen Description  
Agent  Premedications; 
Precautions  Dose  Route  Schedule  Cycle 
Length  
Pembrolizumab  None  200 mg  IV over 30 
minutes before  
paclitaxel  Day 1  
21 (+/- 3) 
days  
(3 weeks)  
 
 
 Paclitaxel  Dexamethasone*  
Famotidine  
Diphenhydramine  80 mg/m2 IV over 60 
minutes; give 
after 
pembrolizumab  Days 1  
and 8  
*Dexamethasone 8 mg IV will be given 30 to 60 minutes before each paclitaxel administration 
during cycle 1. If tolerated,  dexamethasone should  then be tapered to 4 mg at Cycle 2  and 
discontinued at Cycle 3 and beyond for s ubsequent infusions . 
 
 
6.5. Concomitant Medications  
6.5.1.  Acceptable Concomitant Medications  
All treatments that the investigator considers necessary for a subject’s welfare may be 
administered at the discretion of the investigator in keeping with the community 
standards of medical care.  All concomitant medication will be recorded including all 
prescription, over -the-counter (OTC), herbal supplements, and IV medications and fluids.  
If changes occur during the trial period, documentation of drug dosage, frequency, route, 
and date may also be recorded . All concomitant medications used within 28 days before 
the first dose of  study  treatment should be recorded.   
 
6.5.2.  Prohibited Concomitant Medications  
Subjects are prohibited from receiving the following therapies during the screening and 
treatment phase of this trial:  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
33 
 • Immunotherapy not specified in this protocol  
• Chemotherapy not specified in this protocol  
• Investigational agents other than pembrolizumab  
• Radiation therapy  
• Live vaccines within 30 days prior to the first dose  of study  treatment and while 
participating in the trial.  Examples of live vaccines include, but are not limited to, 
the following: measles, mumps, rubella, varicella/zoster, yellow fever, intranasal 
influenza, rabies, BCG, and typhoid vaccine.  
• Gluco corticoids for any purpose other than to modulate symptoms from an event 
of suspected immunologic etiology or as premedication for paclitaxel.   
o Note: The use of physiologic doses of corticosteroids may be approved 
after consultation with the Sponsor -Inves tigator.  
o Note: Inhaled steroids are allowed for management of asthma.  
o Note:  Use of prophylactic corticosteroids to avoid allergic reactions (i.e., 
to IV contract dye) is permitted.  
 
6.6. Definition of Pembrolizumab Overdose  
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 
1,000 mg or greater (≥5 times the indicated dose).  No specific information is available 
on the treatment of overdose of pembrolizumab. Appropriate supportive treatment should 
be provided if clinical ly indicated. In the event of overdose, the subject should be 
observed closely for signs of toxicity.  Appropriate supportive treatment should be 
provided if clinically indicated.  
 
6.7. Duration of Therapy  
In the absence of treatment delays due to adverse event(s), study treatment will 
continue until one of the following criteria applies:  
• Disease progression in subjects who have not yet received pembrolizumab 
(Cohort A)  
• Confirmed disease progression  in subj ects receiving pembrolizumab  
• Disease progression if clinically unstable  
• Unacceptable adverse event(s)  
• Subject decides to withdraw from  study  treatment or protocol  
• General or specific changes in the subject’s condition render the subject 
unacceptable for fu rther study treatment in the judgment of the Investigator.  
 
Note: In the event the criteria for the final analysis are met, and there are subjects who 
have not yet been discontinued from study treatment, they will continue to receive 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
34 
 therapy beyond the dat e the criteria for the study final analysis are met and until one of 
the above criteria applies.  
 
6.8. Drug Accountability  
All investigational study drugs will be stored at the investigational site in accordance 
with Good Clinical Practice (GCP) and Good Manufa cturing Practices (GMP) 
requirements and will be inaccessible to unauthorized personnel.  
 
An adequate record of receipt, distribution, destruction, or return  of all investigation al 
study drugs must be kept in the form of a Drug Accountability Form. The Investigator, 
or responsible party designated by the Investigator, will maintain a careful record of the 
inventory using the Drug Accountability Form.  
 
6.9. Destruction  
The investigator is responsible for keeping accurate records of the  clinical supplies 
received from Merck or designee,  including the amount remaining at the conclusion of 
the trial. Upon completion or termination of the study, all unused and/or partially used 
investigational product will be destroyed at the site according  to LCI IDS pharmacy 
policies. It is the Investigator’s responsibility to arrange for disposal of all empty 
containers, provided that procedures for proper disposal have been established according 
to applicable federal, state, local and institutional guide lines and procedures, and 
provided that appropriate records of disposal are kept.  
 
7. DOSE MODIFICATIONS  
 
7.1. Pembrolizumab  
Pembrolizumab dose reductions are not applicable to this study.  However, pembrolizumab 
must be withheld for drug -related toxicities and se vere or life -threatening AEs as described 
in Table 2 below. Held doses will not be replaced.  When pembrolizumab is restarted, this 
dose would be considered Day 1 of the subsequent cycle and should be in alignment with the 
new schedule.  If pembrolizumab i s held, paclitaxel may continue, when appropriate.  
 
Adverse events (both non -serious and serious) associated with pembrolizumab exposure may 
represent an immunologic etiology.  These adverse events may occur shortly after the first 
dose or several months a fter the last dose of  study  treatment. See Section 8 for supportive 
care guidelines, including use of corticosteroids, for treatment -related adverse events.  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
1 
  
 
Table 2: Dose Modification and Toxicity Management  Guidelines for Immune -Related Adverse Events  Associated with 
Pembrolizumab  Monotherapy and IO Combinations  
 
 
General instructions:  
1. Severe and life -threatening irAEs  should be treated with IV corticosteroids followed by oral steroids. Other immunosuppressive treatment should begin if the ir AEs 
are not controlled by corticosteroids.  
2. Study intervention  must be permanently discontinued if the irAE does not resolve or the  corticosteroid dose is not ≤10  mg/day within 12 weeks of the last study 
intervention treatment.  
3. The corticosteroid taper should begin when the irAE is ≤ Grade 1 and continue at least 4  weeks.  
4. If study intervention has been withheld, study intervention may resume after the irAE decreased to ≤  Grade  1 after corticosteroid taper.  
irAEs  Toxicity 
Grade 
(CTCAE v5.0 
v4.0) Action With 
Pembrolizumab  Corticosteroid and/or Other 
Therapies  Monitoring and Follow -up 
Pneumonitis  Grade 2  Withhold  •  Administer corticosteroids (initial dose of 
1 to 2  mg/kg prednisone or equivalent) 
followed by taper  
•  Add prophylactic antibiotics for 
opportunistic infections  •  Monitor participants for signs and symptoms of 
pneumonitis  
•  Evaluate  participants with suspected pneumonitis with 
radiographic imaging and initiate corticosteroid treatment  Recurrent 
Grade  2,  
Grade 3 or 4  Permanently 
discontinue  
Diarrhea/Colitis  Grade 2 or 3  Withhold  •  Administer corticosteroids (initial dose of 
1 to 2  mg/kg prednisone or equivalent) 
followed by taper  •  Monitor participants for signs and symptoms of 
enterocolitis (ie, diarrhea, abdominal pain, blood or mucus 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
2 
 Recurrent 
Grade 3 or 
Grade 4  Permanently 
discontinue   in stool with or without fever) and of bowel perforation (ie, 
peritoneal signs and ileus)  
•  Participants with ≥Grade 2 diarrhea suspecting colitis 
should consider GI consultation and performing endoscopy 
to rule out colitis  
•  Participants with diarrhea/colitis should be advised to drink 
liberal quantities of clear fluids. If sufficient  oral fluid 
intake is not feasible, fluid and electrolytes should be 
substituted via IV infusion  
AST  or ALT 
Elevation or 
Increased Bilirubin  Grade 2 a Withhold  •  Administer  corticosteroids (initial dose of 
0.5 to 1  mg/kg prednisone or equivalent) 
followed by taper  •  Monitor with liver function tests (consider weekly or more 
frequently until liver enzyme value returned to baseline or 
is stable)  
Grade 3 b or 4 c Permanently  
discontinue  •  Administer corticosteroids (initial dose of 
1 to 2  mg/kg prednisone or equivalent) 
followed by taper  
T1DM or  
Hyperglycemia  New onset 
T1DM or  
Grade 3 or 4 
hyperglycemia 
associated with 
evidence of 
-cell failure  Withhold d •  Initiate insulin replacement therapy for 
participants with T1DM  
•  Administer antihyperglycemic in 
participants with hyperglycemia  
 •  Monitor  participants for hyperglycemia or other signs and 
symptoms of diabetes  
Endocrine disorder s-
other ( Hhypophysitis ) Grade 2  Withhold  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
3 
 Grade 3 or 4  Withhold  or 
permanently 
discontinue d •  Administer corticosteroids and initiate 
hormonal  replacements as clinically 
indicated  •  Monitor for signs and symptoms of hypophysitis ( including  
hypopituitarism and adrenal insufficiency)  
Hyperthyroidism  Grade 2  Continue  •  Treat  with non selective  beta-blockers 
(eg, propranolol) or thionamides as 
appropriate  •  Monitor for signs and symptoms  of thyroid disorders  
Grade 3 or 4  Withhold or 
permanently 
discontinue d 
Hypothyroidism  Grade 2, 3 or 4  Continue  •  Initiate  thyroid replacement hormones 
(eg, levothyroxine or liothyronine) per 
standard of care  •  Monitor for signs and symptoms  of thyroid disorders  
Nephritis:  
grading according to 
increased creatinine 
or acute kidney injury  Grade 2  Withhold  •  Administer corticosteroids (prednisone 1 
to 2 mg/kg or equivalent ) followed by 
taper  •  Monitor  changes of renal function  
Grade 3 or 4  Permanently 
discontinue  
Neurological 
Toxicities  Grade 2  Withhold  •  Based on severity of AE administer 
corticosteroids  •  Ensure  adequate evaluation to confirm etiology and/or 
exclude other causes  Grade 3 or 4  Permanently 
discontinue  
Myocarditis  Grade 1  Withhold  •  Based on severity of AE administer 
corticosteroids  •  Ensure  adequate evaluation to confirm etiology and/or 
exclude other causes  
 Grade 2, 3 or 4  Permanently 
discontinue  
Exfoliative 
Dermatologic 
Conditions  Suspected  SJS, 
TEN, or 
DRESS  Withhold  •  Based on severity of AE administer 
corticosteroids  •  Ensure  adequate evaluation to confirm etiology or exclude 
other causes  
Confirmed SJS, 
TEN, or DRESS  Permanently 
discontinue  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
4 
 All Other irAEs  Persistent  Grade  2 Withhold  •  Based  on severity of AE administer 
corticosteroids  •  Ensure adequate evaluation  to confirm etiology or exclude  
other causes  
Grade 3  Withhold or 
discontinue based 
on the event e  
Recurrent 
Grade  3 or 
Grade  4  Permanently 
discontinue  
AE(s)=adverse event(s); ALT= alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events; DRESS=Drug Rash with 
Eosinophilia and Systemic Symptom; GI=gastrointestinal; IO=immuno -oncology; ir=immune related;  IV=intravenous; SJS=Stevens -Johnson Syndrome; T1DM=type 1 diabetes mellitus; 
TEN=Toxic Epidermal Necrolysis; ULN=upper limit of normal.  
Note: Non -irAE  will be managed as appropriate, following clinical practice recommendations.  
a AST/ALT: >3.0 to5.0 x ULN if baseline normal; >3.0 to 5.0 x baseline, if baseline abnormal;  
bilirubin:>1.5 to 3.0 x ULN if baseline normal; >1.5 to 3.0 x baseline if baseline abnormal  
b AST/ALT: >5.0 to 20.0 x ULN, if baseline normal; >5.0 to 20.0 x baseline, if baseline abnormal; bilirubin:>3.0 to 10.0 x ULN if baseline normal; >3.0 to 10.0 x baseline if baseline 
abnormal  
c AST/ALT: >20.0 x ULN, if baseline normal; >20.0 x bas eline, if baseline abnormal;  
bilirubin:  >10.0  x ULN if baseline normal; >10.0 x baseline if baseline abnormal  
d The decision to withhold or permanently discontinue pembrolizumab is at the discretion of the investigator or treating physic ian. If control ac hieved or ≤  Grade 2, pembrolizumab may be 
resumed.  
e Events that require discontinuation include, but are not limited to: encephalitis and other clinically important irAEs (eg, v asculitis and sclerosing cholangitis).  
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
1 
 Dosing interruptions are permitted in the case of medical / surgical events or logistical reasons 
not related to study therapy (e.g., elective surgery, unrelated medical events, subject  vacation, 
and/or holidays). Subjects should be placed back on study th erapy within 3 weeks of the 
scheduled interruption, unless otherwise discussed with the Sponsor -Investigator. The reason for 
interruption should be documented in the patient's study record . 
See Section 8.1 for supportive care measures to be taken for poten tial immune -related 
toxicities associated with pembrolizumab.  
  
7.2. Paclitaxel  
Each paclitaxel cycle is defined as two paclitaxel treatments given during a 21 -day period.  If 
paclitaxel is held for ≥ 2 weeks, the following instructions apply:  
 
If paclitaxel is held, resume with the missed treatment dose, e.g., if day 1 paclitaxel is held 
for 7 days, treatment will resume  with the "day 1" paclitaxel dose on calendar day 8 and the 
"day 8" paclitaxel dose will be given on day 15.  (In this case, there is no break in therapy 
during the last week of the cycle.  Paclitaxel doses should be given at least 7 days apart. )  
 
If two paclitaxel treatments have not been given by day 21  (+/- 3 days) , proceed with 
treatment day 1 of the next cycle (if toxicities have resolved according to requirements in the 
dose modification sections/tables).  
 
If paclitaxel is discontinued for neuropathy or musculoskeletal pain or other toxicity, 
pembrolizumab may continue.  
 
Table 3:  Dose levels for paclitaxel  
 Dose Level 0  
Starting Dose  Dose Level −1  Dose Level −2  Dose Level −3  
Paclitaxel  80 mg/m 2 70 mg/m 2 60 mg/m 2 Discontinue  
 
Table 4:  Dose Modifications for paclitaxel  
Note : dose modifications listed below are only for paclitaxel -related toxicities , do not 
modify dose if toxicity is not related to paclitaxel.  
 Toxicity  Paclitaxel  
No toxicity  Maintain dose level  
Febrile Neutropenia  
Grade 3   
Hold until resolved, then  1 dose level  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
2 
 Grade 4  Hold until resolved, then  1 dose level  
Neutropenia * 
Grade 1  
Grade 2  
Grade 3  
Grade 4   
Maintain dose level  
Maintain dose level  
Hold until resolved to ≥1,000/ l, maintain dose level  
Decrease one dose level when resolved to ≤ Grade 2  
Thrombocytopenia * 
Grade 1  
Grade 2  
Grade 3  
Grade 4   
Maintain dose level  
Hold until resolved to ≥75,000/ l, maintain dose level  
Hold until resolved to ≥75,000/ l, maintain dose level  
Hold until resolved to ≥75,000/ l, then  1 dose level  
Clinically Significant Non -
Hematologic Toxicities 
(excluding neuropathy and 
musculoskeletal pain)  
Grade 1  
Grade 2  
Grade 3  
Grade 4   
 
 
Maintain dose level  
Hold until resolved to ≤ Grade 1, maintain dose level  
Hold and then d ecrease one dose level when resolved to ≤ Grade 1  
Hold and then d ecrease one dose level when resolved to ≤ Grade 1  
*Only if present on the scheduled treatment day  
 
Table 5:  Dose Modifications for paclitaxel -related neuropathy  
Paresthesias/Dysesthesias  1–7 Days Duration  Persistent for  7 Days or 
Caused a Dose Delay  
Grade 1  – 
Paresthesias/dysesthesias that 
do not interfere with function  Maintain paclitaxel  dose 
Grade 2  – 
Paresthesias/dysesthesias 
interfering with function, but 
not activities of daily living  Maintain paclitaxel dose a 
 Decrease paclitaxel one dose 
level b 
Grade 3  – 
Paresthesias/dysesthesias with 
pain or with function 
impairment that also interfere 
with activities of daily living  First episode:  
Decrease paclitaxel one dose 
level b 
Second episode:  
Discontinue study therapy  First episode:  
Decrease paclitaxel one dose 
level b or discontinue  
Second episode:  
Discontinue study therapy  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
3 
 Grade 4  – Persistent 
paresthesias/dysesthesias that 
are disabling or life -
threatening  Discontinue study therapy  
a Must be resolved to  grade 1 to receive treatment . 
b Hold paclitaxel for persistent  grade >2 neuropathy.  When  grade 1, resume treatment with 
dose modification.  If grade >2 toxicity persists after 2 weeks of delay, discontinue paclitaxel .  
 
Table 6:  Dose Modifications for paclitaxel -related musculoskeletal pain  
Note: Use of narcotics and NSAIDs is encouraged to  maintain the paclitaxel dose if possible.  
Musculoskeletal Pain  1–7 Days Duration  Persistent for  7 Days or  
Caused a Dose Delay  
Grade 1  
(despite analgesics)  Maintain paclitaxel dose  
Grade 2  
(despite analgesics)  Maintain paclitaxel dose  Maintain paclitaxel dose  
or 
Decrease paclitaxel one dose 
level*  
Grade 3  
(despite analgesics)  First episode:  
Decrease paclitaxel one dose 
level  
 
Second episode:  
Discontinue study therapy  First episode:  
Decrease paclitaxel one dose  
or 
Discontinue study therapy  
Second episode:  
Discontinue study therapy  
Grade 4  
(despite analgesics)  Discontinue study therapy  
* Hold paclitaxel for persistent grade 2 or 3 musculoskeletal pain.  (Targeted therapy can be 
continued while paclitaxel is held.)   When  grade 1, resume treatment with paclitaxel dose 
modification.  If grade 2 or grade 3 toxicity persists after 2 weeks of delay, discontinue study 
therapy.  
 
8. TREATMENT -RELATED ADVERSE EVENTS  
 
8.1. Adverse Events Related to Pembrolizumab  
8.1.1.  General Considerations  
Subjects should receive appropriate supportive care measures as deemed necessary 
by the treating investigator.  Suggested supportive care measures for the 
management of adverse events with potential immunologic etiology are outlined 
below. Where appropriat e, these guidelines include treatment with  oral or 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
4 
 intravenous corticosteroids as well as additional anti -inflammatory agents if 
symptoms do not improve with administration of corticosteroids.   Note that several 
courses of steroid tapering may be necessar y as symptoms may worsen when the 
steroid dose is decreased. For each disorder, attempts should be made to rule out 
other causes such as metastatic disease or bacterial or viral infection, which might 
require additional supportive care. The treatment guide lines are intended to be 
applied when the investigator determines the events to be related to pembrolizumab.  
 
Note: if after the evaluation the event is determined not to be related, the 
investigator does not need to follow the treatment guidance as outli ned below. Refer 
to Section 7 for dose modification.   
 
It may be necessary to perform conditional procedures such as bronchoscopy, 
endoscopy, or skin photography as part of evaluation of the event.  
 
8.1.2.  Pneumonitis  
• For Grade 2 events, treat with systemic cort icosteroids. When symptoms improve 
to Grade 1 or less, steroid taper should be started and continued over no less than 
4 weeks.  
• For Grade 3 -4 events, immediately treat with intravenous steroids. Administer 
additional anti -inflammatory measures, as needed.   
• Add prophylactic antibiotics for opportunistic infections in the case of prolonged 
steroid administration .  
 
8.1.3.  Diarrhea/Colitis  
Subjects should be carefully monitored for signs and symptoms of enterocolitis 
(e.g., diarrhea, abdominal pain, blood or mucus i n stool, with or without fever) and 
of bowel perforation ( e.g., peritoneal signs and ileus).  
   
• All subjects who experience diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and 
electrolytes should be substituted via IV infusion.   
• For Grade 2 or higher diarrhea, co nsider gastrointestinal (GI) consultation and 
endoscopy to confirm or rule out colitis.  
• For Grade 2 diarrhea/colitis administer oral corticosteroids .  
• For Grade 3 or 4 diarrhea/colitis , treat with intravenous steroids followed by high 
dose oral steroids.  
• When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.  
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
5 
 8.1.4.  Type 1 Diabetes  (if new onset, including diabetic ketoacidosis [DKA]) or ≥ 
Grade 3 Hyperglycemia, if associated with ketosis (ketonuria) or  metabolic 
acidosis (DKA)  
For T1DM or Grade 3 -4 Hyperglycemia  
• Insulin replacement therapy is recommended for Type I diabetes mellitus 
and for Grade 3 -4 hyperglycemia associated with metabolic acidosis or 
ketonuria.  
• Evaluate subjects  with serum glucose and a metabolic panel, urine 
ketones, glycosylated hemoglobin, an d C-peptide  
 
8.1.5.  Hypophysitis  
• For Grade 2 events, treat with systemic corticosteroids. When symptoms improve 
to Grade 1 or less, steroid taper should be started and continued over no less than 
4 weeks. Replacement of appropriate hormones may be required as the  steroid 
dose is tapered.  
• For Grade 3 -4 events, treat with an initial dose of IV corticosteroids followed by 
oral corticosteroids. When symptoms improve to Grade 1 or less, steroid taper 
should be started and continued over no less than 4 weeks. Replacemen t of 
appropriate hormones may be required as the steroid dose is tapered .  
 
8.1.6.  Hyperthyroidism and Hypothyroidism  
Thyroid disorders can occur at any time during treatment. Monitor subjects  for 
changes in thyroid function (at the start of treatment, periodically during treatment, 
and as indicated based on clinical evaluation) and for clinical signs and symptoms 
of thyroid disorders.  
 
• Grade 2 hyperthyroidism events (and Grade 2 -4 hypothyroid ism):  
o In hyperthyroidism, non -selective beta -blockers (e.g. propranolol) are 
suggested as initial therapy.  
o In hypothyroidism, thyroid hormone replacement therapy, with 
levothyroxine or liothyronine, is in dicated per standard of care.  
• Grade 3 -4 hyperthyro idism  
o Treat with an initial dose of IV corticosteroid followed by oral 
corticosteroids.  
o When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less than 4 weeks.  
o Replacement of appropriate hormones may be require d as the steroid dose 
is tapered.  
 
8.1.7.  Hepatic  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
6 
 • For Grade 2  events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).  
o Treat with IV or oral corticosteroids  
• For Grade 3 -4 events, treat with intravenous corticostero ids for 24 to 48 hours.  
• When symptoms improve to Grade 1 or less, a steroid taper should be started and 
continued over no less than 4 weeks.  
 
8.1.8.  Renal Failure or Nephritis  
• For Grade 2 events, treat with corticosteroids.  
• For Grade 3 -4 events, treat with systemic corticosteroids.  
• When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.  
 
8.1.9.  Management of Infusion Reaction s 
Signs and symptoms usually develop during or shortly after drug infusion and 
generally resolve completely within 24 hours of completion of infusion. Table 7 
below shows treatment guidelines for subjects who experience an infusion reaction 
associated with  administration of pembrolizumab.  Subjects who experience an 
infusion reaction associated with administration of paclitaxel should be treated per 
institutional policy.  
 
Table 7: Pembrolizumab Infusion Reaction Treatment Guidelines  
NCI CTCAE Grade  Treatment  Premedication at subsequent 
dosing  
Grade 1  
Mild reaction; infusion interruption 
not indicated; intervention not 
indicated  Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the investigator.  None  
Grade 2  
Requires infusion interruption but 
responds promptly to symptomatic 
treatment (e.g., antihistamines, 
NSAIDS, narcotics, IV fluids); 
prophylactic medications indicated for 
< =24 hrs  Stop Infusion and monitor symptoms.  
Additional appropriate medical therapy may 
include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the treating investigator.  
If symptoms resolve within one hour of stopping 
drug infusion, the infusion may be restarted at 
50% of the o riginal infusion rate (e.g., from 100 
mL/hr to 50 mL/hr).  Otherwise dosing will be 
held until symptoms resolve and the subject Subject may be premedicated 1.5h 
(± 30 minutes) prior to infusion of 
pembrolizumab (MK -3475) with:  
 
Diphenhydramine 50 mg po (or 
equivalent dose of antihistamine).  
 
Acetaminophen 500 -1000 mg po 
(or equivalent dose of antipyretic).  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
7 
 NCI CTCAE Grade  Treatment  Premedication at subsequent 
dosing  
should be premedicated for the next scheduled 
dose.  
Subjects who develop Grade 2 toxicity despite 
adequate premedication should be 
permanently discontinued from further trial 
treatme nt administration.  
Grades 3 or 4  
Grade 3:  
Prolonged (i.e., not rapidly responsive 
to symptomatic medication and/or 
brief interruption of infusion); 
recurrence of symptoms following 
initial improvement; hospitalization 
indicate d for other clinical sequelae 
(e.g., renal impairment, pulmonary 
infiltrates)  
Grade 4:  
Life-threatening; pressor or ventilatory 
support indicated  Stop Infusion.  
Additional appropriate medical therapy may 
include but is not limited to:  
IV fluids  
Antihistamines  
NSAIDS  
Acetaminophen  
Narcotics  
Oxygen  
Pressors  
Corticosteroids  
Epinephrine  
 
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the investigator.  
Hospitalization may be ind icated.  
Subject is permanently discontinued from 
further trial treatment administration.  No subsequent dosing  
 
 
8.1.10.  Reproductive Risks  
Pembrolizumab may have adverse effects on a fetus in utero.  Furthermore, it is not 
known if pembrolizumab has transient adverse effects on the composition of sperm.   
For this trial, male subjects will be considered to be of non -reproductive potential if 
they have azoospermia (whether due to having had a vasectomy or due to an 
underlying medical condition).   
 
Female subjects will be considered of non -reproductive potential if they are either:  
1) postmenopausal (defined as at least 12 months with no menses w ithout an 
alternative medical cause; in women < 45 years of age a high follicle 
stimulating hormone (FSH) , luteini zing hormone (LH), and estradiol levels  
in the postmenopausal range may be used to confirm a post -menopausal 
state in women not using hormonal contraception or hormonal replacement 
therapy.  
OR  
2) have had a hysterectomy and/or bilateral oophorectomy, bilateral 
salpingectomy or bilateral tubal li gation/occlusion.  
OR  
3) has a congenital or acquired condition that prevents childbearing.  
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
8 
 Female and male subjects of reproductive potential must agree to avoid becoming 
pregnant or impregnating a partner, respectively, while receiving study  treatment  
and for 120 days after the last dose of study treatment  by complying with one of th e 
following:  
   
1) practice abstinence from heterosexual activity;  
OR  
2) use (or have their partner use) acceptable contraception during heterosexual 
activity.   
 
Acceptable methods of contraception are:  
  
Single method (one of the following is acceptable):  
• Intrauterine device (IUD)  
• Vasectomy of a female subject’s male partner  
• Contraceptive rod implanted into the skin  
  
Combination method (requires use of two of the following):  
• Diaphragm with spermicide (cannot be used in conjunction with cervical 
cap/spermici de) 
• Cervical cap with spermicide (nulliparous women only)   
• Contraceptive sponge (nulliparous women only)  
• Male condom or female condom (cannot be used together)  
• Hormonal contraceptive: oral contraceptive pill (estrogen/progestin pill or 
progestin -only pill), contraceptive skin patch, vaginal contraceptive ring, or 
subcutaneous contraceptive injection  
 
Note: Abstinence (relative to heterosexual activity) can be used as the sole 
method of contraception if it is consistently employed as the subject’s 
preferred and usual lifestyle and if considered acceptable by local regulatory 
agencies and IRBs.  Periodic  abstinence (e.g., calendar, ovulation, sympto -
thermal, post -ovulation methods, etc.) and withdrawal are not acceptable 
methods of contraception.  
 
Subjects should be informed that taking the study therapy  may involve unknown 
risks to the fetus (unborn bab y) if pregnancy were to occur during the study.  In 
order to participate in the study subjects of childbearing potential must adhere to the 
contraception requirement (described above) from the day of study medication 
initiation (or 14 days prior to the ini tiation of study therapy  for oral contraception) 
throughout the study period up to 120 days after the last dose of study  therapy.  If 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
9 
 there is any question that a subject of childbearing potential will not reliably comply 
with the requirements for contrace ption, that subject should not be entered into the 
study.  
 
9. DATA AND SAFETY MONITORING PLAN  
 
9.1. Safety Monitoring  
This protocol will be monitored according to the processes in effect for all Levine Cancer 
Institute investigator -initiated studies and the protoc ol-specific monitoring plan, and will 
abide by standard operating procedures set forth by both the Atrium Health  Office of Clinical 
and Translational Research and the Levine Cancer Institute Clinical Trials Office.  It is the 
responsibility of the Sponsor -Investigator to monitor the safety data for this study.  The 
Sponsor -Investigator, Statistician, and other team members as needed will meet regularly to 
monitor subject consents, enrollment and retention, safety data for all subj ects [including 
adverse events (AEs) for all grades and attributions, serious adverse e vents (SAE s)], study  
treatment  administration, and validity/integrity of the data.  Documentation of these meetings 
will be kept with study records.  SAEs will be reported to the Food and Drug Administration 
(FDA) and the IRB per their requirements.  Major protocol deviations that result in a threat to 
subject safety or the integrity of the study will be reported to the FDA and IRB per their 
requirements.  The Spons or-Investigator will submit data to the LCI Data and Safety 
Monitoring Committee according to the overarching LCI Data and Safety Monitoring Plan.  
 
9.2. Data Quality Assurance  
This study will be organized, performed, and reported in compliance with the study pr otocol, 
standard operating procedures (SOPs) of the Levine Cancer Institute and Atrium Health  
Office of Clinical and Translational Research, the FDA, and other applicable regulations and 
guidelines (e.g. GCP).  
 
Subject data will be monitored by Levine Cancer Institute Research Monitors routinely for 
data quality.  This monitoring will be done by comparing source documentation to the 
eCRFs.  Any variation between the two data sets will be discussed with the Sponsor -
Investigato r and/or appropriate research personnel.  
 
The study database will be reviewed and checked for omissions, apparent errors, and values 
requiring further clarification using computerized and manual procedures.  Data queries 
requiring clarification will be gen erated and addressed by the appropriate study team member 
and/or Sponsor -Investigator.  Only authorized personnel will make corrections to the study 
database and all corrections will be documented in an electronic audit trail.  
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
10 
 9.3. Communication Between Sites  
Investigational sites will be required to report applicable AEs, SAEs, deviations or any other 
problem that could affect the validity/integrity of the study data to the Sponsor -Investigator.    
AEs will be reported within 10 business days of the investigator learning of the event.  SAEs 
will be reported within 1 busin ess day  of the investigator learning of the event.  Drug 
administration or any other problem affecting subject safety or the integrity of the data 
should be communicated to the Sponsor -Investigator in writing as soon as possible but within 
2 business days of learning of the event.  
 
10. SAFETY DATA COLLECTION, RECORDING AND REPORTING  
 
Safety assessments will consist of monitoring and recording all adverse events and serious 
adverse events, regular monitoring of hematology, blood chemistry and liver function test 
values, regular measurement of vital s igns, and performance of history and physical 
examinations.  These assessments should be performed per the study calendar . Adverse 
events  will be evaluated continuously throughout the study. Safety and tolerability, 
relationship to  study treatment and intensity will be assessed according to the Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0 . All adverse events (Grades 1 
– 5) will be documented in subject study charts, and recorded in the eCRF.  
 
10.1. Unanticipated Problem De finition  
An UAP is any incidence, experience or outcome that is unexpected, given the information 
provided in research -related documentation ( e.g., Investigator’s brochure, informed consent) 
and the study population characteristics that is related or possi bly related to participation in 
the research study and places the participant at an increased risk.   
 
10.2. Adverse Event  
10.2.1.  Adverse Event Definition  
An adverse event or adverse experience is any untoward medical occurrence in a study 
subject who is administered a  study drug that does not necessarily have a causal 
relationship with this study treatment.  An adverse event can therefore be any unfavorable 
and unintended sign, symptom, or disease temporally associated with the use of the study 
drug, whether or not con sidered related to the study drug.  Pre -existing conditions that 
increase in frequency or severity or change in nature during or as a consequence of use of 
a drug in human clinical trials are also considered adverse events.   
 
Any continuing medical condit ion or clinically significant laboratory abnormality with an 
onset date before the first date of study treatment  administration should be considered 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
11 
 pre-existing and should be documented in the subject’s medical records and /or in the 
study chart  at baseline . If the medical condition or clinical ly significant laboratory 
abnormality worsens while the patient is on study, it should be documented as an adverse 
event.  
 
10.2.2.  An Adverse Event does not include  
An AE does not include:  
• relapse or progression o f the underlying malignant disease; however, the 
associated  signs, symptoms, or diagnoses should be recorded as adverse 
events  (e.g., “jaundice” due to new or increasing liver metastases, or “tumor 
pain” or “bone pain” due to progressive disease);  
• medical  or surgical procedures (e.g., surgery, endoscopy, tooth extraction, 
transfusion).  The condition that leads to the procedure is the adverse event;  
• situations where an untoward medical occurrence has not occurred (e.g., 
hospitalization for elective surger y, social and/or convenience admissions);  
• overdose of paclitaxel or concomitant medication without any signs or  
symptoms unless the subject  is hospitalized for observatio n 
 
 
Laboratory abnormalities are usually not recorded as adverse events; however, signs  
and/or symptoms that are associated with laboratory findings requiring study 
withdrawal, dose modification, or medical intervention (e.g., anemia requiring 
transfusions or hyperglycemia requiring treatment) or other abnormal assessments 
(e.g., ECG, radiographs, vital signs) must be recorded as adverse events if they meet 
the definition of an adverse event.  In addition, laboratory abnormalities marked as 
clinically significant by the investigator should also be recorded as adverse events in 
the eCRF.  The investigator will record all clinically significant grade s for laboratory 
abnormalit ies and will evaluate their relationship to the study treatment  and subject’s 
clinical condition if/when a clinically significant laboratory abnormality occur s. 
 
10.2.3.  Relationship to Study  Treatment  
The relationship to study treatment  therapy should be assessed using the following 
definitions:   
 
Not Related:   Evidence exists that the AE has an etiology other than the study  treatment  
(i.e., pre -existing condition, underlying disease, intercurrent illness, or concomitant 
medication).  This includes events that are considered remotely or unlikely related t o 
study  treatment . 
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
12 
 Related:   A temporal relationship exists between the event onset and administration of the 
study  treatment .  It cannot be readily explained by the subject’s clinical state, intercurrent 
illness, or concomitant therapies.  In t he case of cessation or reduction of the dose, the 
event abates or resolves and reappears upon rechallenge.  It should be emphasized that 
ineffective study treatment should not be considered as causally related in the context of 
AE reporting.  This in cludes events that are considered possibly, probably, or definitely 
related to study  treatment . 
 
All adverse events (including event name, grade, start/stop date and attribution) will be 
documented in the medical record and on the case report form for  this protocol.  
 
The Investigator is responsible for verifying and providing source documentation for all 
adverse events and assigning the attribution for each event for all subjects enrolled on the 
trial. 
 
10.3. Suspected Adverse Reaction Definition  
A SAR is an adverse event in which there is reasonable possibility that the study treatment  
caused the adverse event as defined by 21 CFR 312.32.  The Investigator is responsible for 
judging whether it is a reasonable possibility that the study  treatment  caused the adverse 
event.  
 
10.4. “Unexpected” Definition  
An AE or SAR is to be considered unexpected if the event is not listed in the current 
Investigator Brochure, package insert or label or is not listed in the severity or specificity 
observed.  
 
10.5. Serious Adverse Event Definition  
Adverse events may also be considered serious adverse events. Serious adverse event or SAE 
shall mean any untoward medical occurrence in a study subject who is administered the study 
treatment  that results in :  
• Death;  
• Life-threatening situation (subject  is at immediate risk of death);  
• Inpatient hospitalization or prolongation of an existing hospitalization ( excluding 
those for study  treatment  administration, protocol -related procedures , palliative or 
hospice care, or placement of an indwelling catheter , unless associated with other 
serious events);  
• Persistent or significant disability/incapacity;  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
13 
 • Congenital anomaly/birth defect in the offspring of a patient who received study  
treatment ;  
• A new cancer if the cancer is the condition of the study ; or 
• Other:  Important medical events that may not result in death, be immediately life -
threatening, or require hospitalization, may be considered an SAE when, based upon 
appropriate medical judgment,  they may jeopardize the subject  or may require 
medical or surgical intervention to prevent one of the outcomes listed in this 
definition.    
o Examples of such events are:  
▪ Intensive treatment in an emergency room or at home for allergic 
bronchospa sm;  
▪ Blood dyscrasias or convulsions that do not result in hospitalization;  
▪ Development of drug dependency or drug abuse.   
 
The following events do not meet the criteria for seriousness per ICH definition, but must be 
reported in the same manner as SAEs. Therefore, these events are considered serious for 
collection purposes:  
• Pregnancy or lactation  
• Overdose of pembrolizumab, as defined in Section 6.6  
 
10.6. Safety Reporting to the Sponsor -Investigator  
SAEs must be reported to the Sponsor -Investigator within 1 business day of awareness .  
SAEs will be captured from the time of  study  treatment initiation  through 90 days after the 
date of the last study  treatment  administration  or 30 days following cessation of treatment if 
the subject initiates new anti -cancer therapy, whichever is earlier . Events that meet the 
definition of an SAE that are determined to be related and unexpected to a research 
procedure  or study treatment  are reportable starting with informed consent  throughout the 
duration of the subject’s participation. In addition, once study treatment is initiated,  SAEs 
that are determined to be related to pembrolizumab  or a study procedure  (regardle ss of 
expectedness)  are reportable  through the duration of the subject’s participation on the trial  
(treatment and follow -up). SAEs will be followed until clinical recovery is complete and 
laboratory tests have returned to baseline, until progression has b een stabilized, or until there 
has been acceptable resolution of the event. This may at times cause the follow -up period for 
SAEs to be greater than 90 days.  Similarly, the Sponsor -Investigator is responsible for 
following the subject during the required follow -up period even if the subject lives elsewhere 
or has been released from his or her care and is being treated under another service at LCI.  
10.7. Safety Reporting to the FDA  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
14 
 For investigator -initiated studies where the Sponsor -Investigator holds an IND, sa fety 
reporting requirements for the FDA apply in accordance with the guidance set forth in 21 
CFR312.32. The Sponsor -Investigator, or research designee, will be responsible for notifying 
FDA (using a MedWatch form) and all participating Investigators of an y unexpected fatal or 
life-threatening suspected adverse reaction as soon as possible, but in no case later than 7 
calendar days after the Sponsor's initial receipt of the information. For all other serious and 
unexpected safety events, the Sponsor -Investi gator, or research designee, will notify the FDA 
within 15 calendar days.  
 
It is the responsibility of the Sponsor -Investigator, Investigators and the Protocol Team to 
ensure SAEs are reported according to the Code of Federal Regulations, Good Clinical 
Practices, the protocol guidelines, Institutional Review Board, and FDA policy.  
 
Planned protocol deviations will be submitted to the FDA for prior approval only if the 
deviation affects the scientific validity of the study and/or the rights, safety, or welfa re of 
subjects.  
 
10.8. Safety Reporting to the IRB  
All UAPs , protocol deviations  and SAEs occurring during the conduct of a protocol will be 
reported to the IRB per IRB reporting requirements . 
 
10.9. Safety Reporting to Merck  
All SAEs meeting the definition of an SAE in Section 10.5 will be reportable  to Merck .   
Any serious adverse event, or follow up to a serious adverse event, including death due to 
any cause other than progression of the cancer under study that occurs to an y subject from 
the time of study treatment initiation  through 90 days following cessation of  study  treatment, 
or 30 days following cessation of  study  treatment if the subject initiates new anti -cancer 
therapy, whichever is earlier, whether or not related to pembrolizumab , will be reported 
within 2 working days of Sponsor -Investigator awareness to Merck Global Safety  by the 
Sponsor -Investigator .  
 
Addit ionally, any serious adverse event, considered by an investigator who is a qualified 
physician to be related to pembrolizumab  that is brought to the attention of the investigator at 
any time outside of the time period specified in the previous paragraph al so must be reported 
immediately to the Sponsor -Investigator  and to Merck.  
 
SAE reports and any other relevant safety information are to be forwarded to Merck  by the 
Sponsor -Investigator  to Global Safety facsimile number:  +1 -215-993-1220  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
15 
  
If the Sponsor -Investigator holds an IND, a  copy of all 15 Day Reports and Annual Progress 
Reports are to be submitted as required by the FDA or other local regulators. Investigators 
will cross reference this submission according to local regulations to the Merck 
Investiga tional Compound Number (IND, CSA, etc.) at the time of submission.  
Additionally , investigators will submit a copy of these reports to Merck & Co., Inc. (Attn: 
Worldwide Product Safety; FAX 215 993 -1220) at the time of submission to the appropriate 
regulat ory agency . 
 
10.9.1.  Evaluating Adverse Events  
The treating  investigator or qualified designee  will evaluate all adverse events 
according to the NCI Common Terminology for Adverse Events (CTCAE), version 
4.0. Any adverse event which changes CTCAE grade over the course of a given 
episode will have each change of grade recorded on the adverse event c ase report 
forms/worksheets.  
 
All adverse events regardless of CTCAE grade must also be evaluated for 
seriousness.  
 
11. MEASUREMENT OF EFFECT  
 
11.1. Anti -tumor Effect – Solid Tumor  
Response and progression will be evaluated in this study using the revised response 
evaluation criteria in solid tumors (RECIST) guideline version 1.1.  
 
11.1.1.  Disease Parameters  
For the purposes of this study, subjects  should be reevaluated for response  per section 
4.5.6 . In addition to the baseline scan(s), confirmatory scans should a lso be obtained 
not less than 4 weeks following initial documentation of objective response. Changes 
in the largest diameter (unidimensional measurement) of the tumor lesions , or shortest 
axis for lymph nodes, are used in the RECIST criteria.   
Note:  Lesio ns are either measurable or non -measurable using the criteria provided 
below. The term “evaluable” in reference to measurability will not be used because it 
does not provide additional meaning or accuracy.  
 
Target lesions:  When more than one measurable l esion is present at baseline , all 
lesions up to a maximum of five lesions total (and a maximum of two lesions per 
organ) representative of all involved organs should be identified as target lesions and 
will be recorded and measured at baseline. Target lesions should be selected on the 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
16 
 basis of their size (lesions with the longest diameter), be representative of all involved 
organs, but in addition should be those that lend themselves to reproducible repeated 
measurements. It may be the case that,  on occasion, the largest lesion does not lend 
itself to reproducible measurement in which circumstance the next largest lesion 
which can be measured reproducibly should be selected. Lymph nodes merit special 
mention since they are normal anatomical struct ures which may be visible by imaging 
even if not involved by tumor. Pathological nodes , which are defined as measurable 
and may be identified as target lesions , must meet the criterion of a short axis of ≥ 15 
mm by CT scan. Only the short axis of these nod es will contribute to the baseline 
sum. The short axis of the node is the diameter normally used by radiologists to judge 
if a node is involved by solid tumor. Nodal size is normally reported as two 
dimensions in the plane in which the image is obtained (f or CT scan this is almost 
always the axial plane). The smaller of these measures is the short axis. All other 
pathological nodes (those with short axis ≥ 10 mm but <15 mm) should be considered 
nontarget lesions. Nodes that have a short axis <10 mm are cons idered 
nonpathological and should not be recorded or followed. A sum of the diameters 
(longest for non -nodal lesions, short axis for nodal lesions) for all target lesions will 
be calculated and reported as the baseline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum. 
The baseline sum diameters will be used as reference to further characterize any 
objective tumor regression in the measurable dimension of the disease.  
 
Non-target les ions: All other lesions (or sites of disease) including pathological 
lymph nodes should be identified as non -target lesions and should also be followed as 
‘present’, ‘absent’, or in rare cases ‘unequivocal progression’.  
 
11.1.2.  Methods  
All measurements should be taken and recorded in metric notation using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to the 
beginning of  study treatment and never more than 4 weeks before the beginning of 
study  treatment.  
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline and during follow -up. 
Imaging -based evaluation is preferred to evaluation by clinical examination when 
both methods have bee n used to assess the anti -tumor effect of a treatment.  The 
Sponsor -Investigator or designee will be responsible for performing tumor 
measurements.  The tumor measurements will be recorded  on the eCRF.  
 
11.1.3.  Response Criteria  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
17 
 Response will be evaluated using RE CIST 1.1 Criteria.  
 Complete Response : 
• Target lesion: Disappearance of all target lesions. Any pathological lymph   
 nodes (whether target or non -target) must have reduction in short axis to   
 <10 mm. 
• Non-target lesion: Disappearance of all non -target lesions. All lymph nodes   
 must be non -pathological in size (<10  mm short axis).  
 
Partial Response : 
• Target lesion: At l east a 30% decrease in the sum of diameters of target,  
 taking as reference the baseline sum diameters.  
• Non-target lesion: Not applicable  
 
Stable Disease : 
• Target lesion: Neither sufficient shrinkage to qualify for a partial response,   
 nor sufficient increase to qualify for progressive disease, taking as reference   
 the smallest sum diameters while on study.  
• Non-target lesion: Not applicable.  
 
Progressive Disease : 
• Target lesion: At least a 20% increase in the sum of diameters of target   
 lesions, taking as reference the smallest sum on study  (this includes the   
 baseline sum if that is the smallest on study). In addition to the relative   
 increase of 20%, the sum must also demonstrate an absolute increase of at  
 least 5  mm. ( Note:  the appearance of one or more new lesions is also 
considered progression).  
• Non-target lesion: Unequivocal progression  (as described in RECIST version   
 1.1) of existing non -target lesions. ( Note:  the appearance of one or more new   
 lesions is also considered progression).  
 
Non-Complete Response / Non -Progressive Disease : 
• Target lesion: Not applicable  
• Non-target lesion: Persistence of one or more non -target lesion(s)  
 
  Table 8: Summary of RECIST 1.1  (Subjects with measurable disease)  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
18 
  
 
 
 
 
 
 
Table 9: Summary of RECIST 1.1 (Subjects with non -target disease only)  
 
RECIST 1.1 will be adapted as follows to account for the unique tumor response seen in 
this class of therapeutics, irRECIST .   
 
If imaging shows PD, tumor assessment should be repeated ≥4 weeks later in order to 
confirm PD with the option of continuing treatment for clinically stable subjects as 
discussed below in Table 10.   
 
Clinically stable is defined by the following criteria:    
• Absence of signs and symptoms indicating disease progression  
• No decline in ECOG performance status  
• Absence of rapid progression of disease  Target 
Lesions  Non-target Lesions  New Lesions  Overall 
Response  Best Response for this  
Category also requires  
CR CR No CR Documented at least once 
 4 weeks from baseline  
CR Not-evaluated  No PR NA 
CR Non-CR/Non -PD No PR Documented at least once 
 4 weeks from baseline  PR Non-PD or NE  No PR 
SD Non-PD or NE  No SD Documented at least once 
 4 weeks from baseline  
Not all 
evaluated  Non-PD No NE NA 
PD Any Yes or No  PD 
No prior SD, PR or CR  Any PD* Yes or No  PD 
Any Any Yes PD 
* In exceptional circumstances , unequivocal progression in nontarget lesions may be accepted as disease progression.  
Non-target Lesions  New Lesions  Overall Response  
CR No CR 
Non-CR/Non -PD No Non-CR/ Non -PD 
Not all evaluated  No NE 
Unequivocal PD  Yes or No  PD 
Any Yes PD 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
19 
 • Absence of progressive tumor at critical anatomical sites (e.g., cord 
compression) requiring urgent alternative  medical intervention  
       
Table 10: irRECIST: Imaging and Treatment after 1st Radiologic Evidence of PD   
 Clinically Stable  Clinically Unstable  
Imaging  Treatment  Imaging  Treatment  
1st radiologic 
evidence of PD  Repeat imaging at > 4 
weeks at site to 
confirm PD  May continue study 
treatment at the 
Investigator’s 
discretion while 
awaiting confirmatory 
scan by site  N/A Discontinue treatment  
Repeat scan confirms 
PD No additional imaging 
required  Discontinue treatment 
(exception is possible 
upon consultation 
with Sponsor).  N/A 
No additional imaging 
required  N/A 
Repeat scan shows 
SD, PR or CR  Continue regularly 
scheduled imaging 
assessments  Continue study 
treatment at the 
Investigator’s 
discretion  N/A N/A 
 
In determin ing whether or not the tumor burden has increased, decreased or stayed stable, site  
investigators should consider all target lesions as well as non -target lesions.  
 
Any subject deemed clinically unstable should be discontinued from study  treatment at first  
evidence of progressive disease by tumor imaging and is not required to have repeat tumor  
imaging for confirmation.  
 
For a clinically stable subject with fir st radiologic evidence of progressive disease (i.e.,  
unconfirmed progression of disease), it is at the discretion of the site investigator to continue  
treating the subject with the assigned study treatment per protocol until progression of disease is  
confirmed at least 28 days from the date of the tumor imaging first suggesting PD.  If  
progression is not confirmed on the subsequent tumor imaging, the subject should continue to  
receive study therapy and have tumor imaging performed as outlined in Sectio n 4.5.6  to monitor 
disease status. If radiologic progression is confirmed by subsequent tumor imaging, then the 
subject will be discontinued from study  treatment.  
 
NOTE: If a subject with confirmed progression by tumor imaging (i.e. two scans at leas t 28 days  
apart demonstrating progressive disease) is clinically stable or clinically improved, and there is  
no further increase in the tumor burden at the confirmatory scan, an exception may be considered  
to continue study treatment upon consultation w ith the Sponsor. Subjects exhibiting intolerable 
toxicity from trial therapy may NOT continue to receive trial therapy.  
 
NOTE:  In subjects who discontinue study therapy without documented disease progression, 
every effort should be made to continue monit oring their disease status by tumor imaging as 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
20 
 outlined in Section 4.5.6 until (1) the start of new anti -cancer treatment, (2) disease progression 
(3) death, or (4) the end of the study, whichever occurs first. The same imaging modality (i.e., 
CT or MRI), acquisition and technical parameters should be used throughout the study  for a 
given subject.  
 
12. STATISTICAL CONSIDERATION  
 
12.1. Sample Size  
This is an open -label randomized pilot study designed primarily to evaluate the safety and 
feasibility of the two regimens described earlier (Cohort A [phased regimen] and Cohort B 
[concurrent regimen]), in subjects  with metastatic HER2 -negative breast can cer who have 
received no more than three prior lines of chemotherapy for metastatic disease.  Based on the 
Bayesian stopping rules described in Section 12.4.4, 20 subjects  per arm will enable an 
assessment for each regimen regarding whether or not  evidence  suggests  the overall grade 3 
or 4 study treatment -related adverse event rate convincingly exceeds 0.35 (the reported rate 
for weekly paclitaxel).  Randomization to this study will continue until at least 20 subjects  
per arm have been randomized and begin study therapy.  
 
12.2. Endpoint Definitions  
12.2.1.  Grade 3 or 4  Treatment -Related Adverse Event  
Grade 3 or 4  study treatment -related adverse event s will be determined for each 
subject  as a binary variable indicating whether or not the subject  experienced any 
grade 3 or  4 study treatment -related adverse  events  according to the NCI Common 
Terminology for Adverse Events, version 4.0.   An adverse event will be considered 
study treatment related if it is deter mined  that the event is at least possibly related to 
either paclit axel, pembrolizumab , or both.  
 
12.2.2.  Overall Survival  
Overall survival (OS) is defined as the duration of time from randomization to death 
from any cause. Subjects who are alive or lost to follow -up at the time of the 
analysis will be censored at the last known date they were alive.  
 
12.2.3.  Progression -Free Survival  
Progression -Free Survival (PFS) is defined as the duration of time from 
randomization to first occurrence of either progressive disease or death. Disease 
progression must  be objectively determined as p er Section 11 , where the date of 
progression is the date of the radiologic assessment that identified progressive 
disease.  If the subject died without documented disease progression, the date of 
progression will be the date of death. For surviving subject s who do not have 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
21 
 documented disease progression, PFS will be censored at the date of last radiologic 
assessment. For subjects who receive subsequent anti -cancer therapy prior to 
documented disease progression, PFS will be censored at the date of last radi ologic 
assessment prior to the commencement of subsequent therapy. Subjects who have 
an initial PFS event immediately following 2 or more consecutive missed 
assessments will be censored at the date of the last assessment prior to those missed 
assessments. For participants with only one missed assessment, the documented 
progressive disease status and assessment date will be used.   PFS will be determined 
for each subject  using the RECIST 1.1  criteria.  For subjects treated with 
pembrolizumab, PFS will also be  calculated using the irRECIST criteria  as an 
exploratory endpoint . 
 
12.2.4.  Objective Response  
Objective  response will be determined for each subject  as a binary variable 
indicating whether or not the subject  achieved a best overall response of CR or PR 
as determ ined by criteria described in Section 11.   Objective response will be 
determined for each subject  using the RECIST 1.1 criteria.  For subjects treated with 
pembrolizumab, o bjective response will also be calculated using the irRECIST 
criteria as an explorat ory endpoint.  
    
12.2.5.  Duration of Response  
Duration of Response (DoR ) is defined as the duration of time from the first 
assessment that determined a CR or PR to the date of the first occurrence of 
progressive disease or death.  Progression events and the censoring mechanism for 
DoR will be the same as described for PFS in Section 12.2.3.  DoR will be 
determined for each subject  using the RECIST 1.1 criteria.  For subjects treated with 
pembrolizumab, DoR will also be calculated using the irRECIST criteria as an 
exploratory endpoint.  
 
12.2.6.  Disease Control  
Disease  control will be determined for each subject  as a binary variable indicating 
whether o r not the subject  achieved a best overall response of CR, PR, or SD  (for 
at least 24 weeks) , as determined by the criteria described in Section 11.   Disease 
control will be determined for each subject  using the RECIST 1.1 criteria.  For 
subjects treated with pembrolizumab, d isease control will also be calculated using 
the irRECIST criteria as an exploratory endpoint.   
 
12.2.7.  Safety Endpoints  
Safety endpoints will include  study  treatment administration (total number of 
doses taken, and total doses taken as a percent of total number of intended doses), 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
22 
 AEs, SAEs, deaths while on study therapy, and selected laboratory 
determinations.  
 
12.3. Analysis Populations  
The intent -to-treat (ITT) p opulation will consist of all randomized subjects .  The ITT 
population will be used for the purposes of the subject  disposition summary.  The 
evaluable population will consist of all randomized subjects  who begin study therapy.  
OS, PFS, and a ll safety analyses will be conducted on the evaluable population. 
Analyses of objective response , DoR, and disease control  will be conducted on those 
subjects  in the evaluable population who have measureable disease at baseline.  
 
12.4. Analysis Methods  
12.4.1.  Timing of  Analysis  
Analyses on this study will be conducted on a continuous basis in order to assess the 
Bayesian stopping rules for toxicity described in Section 12.4.4.  An analysis of all 
endpoints will occur after the best overall response for each subject  has been determined.  
A final analysis of the study will be conducted after the PFS censoring rate reduces to 
20% or when all subjects  have been on study for at least two years (whichever occurs 
first).  
 
12.4.2.  Subject  Disposition  
An accounting of all consenting subj ects will be provided at the end of the study. This 
will include a breakdown of subjects who consented, were randomized, treated, 
discontinued study treatment, died, and were lost to follow -up or withdrew consent.  
 
12.4.3.  Baseline Patient and Disease Characterist ics 
A summary of subject demographics and disease -related characteristics will be completed 
and subject medical history will be assessed.  
 
12.4.4.  Primary Analysis  
This study is planned to enroll approximately  20 subjects in each study treatment arm. 
The primary objective is to evaluate the overall grade 3 or 4 study treatment related 
adverse event rate for each study arm.  It is not anticipated that the addition of 
pembrolizumab to standard chemotherapy will increase the grade 3 or 4 to xicity rate.  It 
has been reported that the rate of any grade 3 or 4 toxicity with weekly paclitaxel is 0.35 
[Budd, ASCO abstract 2013, CRA1008].  If it becomes evident that the grade 3 or 4 
toxicity rate on either arm convincingly exceeds 0.35, the study arm will be halted. The 
stopping rule will hold enrollment if the posterior probability of grade 3 or 4 toxicity risk 
exceeding 0.35 is 0.50 or higher.  The prior distribution for this monitoring rule is beta  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
23 
 (7,13).  This means that our prior assumption regarding the proportion of grade 3 or 4 
toxicity is 0.35, and there is 90% probability that this proportion is between 0.188 and 
0.530.  The operating characteristics of the stopping rule are given in the following table 
and are based on 5000 s imulations.  
 
Table 1 1: Operating Characteristics of the Stopping Rule  
Number of grade 3 or 
4Toxicities  Max. Denominator Cutoff for Early 
Stopping  Posterior Probability 
Pr(Risk>0.35|Data)  
1 2 0.5352  
2 5 0.5302  
3 8 0.5216  
4 11 0.5148  
5 14 0.5040  
6 16 0.5438  
7 19 0.5334  
 
 
12.4.5.  Secondary Analyses  
Overall survival and PFS will be analyzed by study arm using Kaplan Meier 
techniques.  Medians, 25th, and 75th percentiles will be estimated.  Selected landmarks 
for OS and PFS rate s will be obtained from the Kaplan Meier estimates.  Differences 
between the arms will be assessed qualitatively using a stratified Cox proportional 
hazards model, including hormone rec eptor status as the stratification variable.  An 
estimate of the hazard ratio and 95% confidence interval will be provided .  Duration 
of response will be analyzed in a similar fashion as described for OS and PFS.  
Objective response rate and disease contro l rate will be estimated for each arm along  
with corresponding 95% Clopper -Pearson confidence intervals.  Differences between 
the arms will be assessed qualitatively using a stratified logistic regression, including 
hormone receptor status as the stratific ation variable.  Estimate s of the odds ratio s and 
95% confidence interval s will be provided.   
 
12.4.6.  Safety Analyses  
Incident rates for treatment -emergent adverse events, SAEs, and deaths while on study 
therapy will be summarized.   Treatment -emergent adverse ev ents are defined as follows:  
• An adverse event that occurs after study treatment start that was not present at the 
time of study treatment start; or  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
24 
 • An adverse event that increases in severity after study treatment start if the event 
was present at the time  of study treatment start.  
 
 
12.4.7.  Exploratory  Analyses  
Cox proportional hazards models and logistic regression will be used to assess the 
correlation between additional baseline biomarkers with clinical outcomes.  The 
biomarkers identified in Section 1.4 will be assessed qualitatively as deemed appropriate.  
 
12.5. Interim Analyses  
No formal interim analysis for efficacy is planned for this study.  However, results will 
be continuously monitored for safety using the Bayesian stopping rules described in 
Section 12 .4.4. 
 
13. STUDY COMPLETION  
 
13.1. Completion   
The study will be considered complete when one or more of the following conditions is 
met: 
• All subjects have completed all study visits.  
• All subjects have discontinued from the study.  
• The IRB, FDA, LCI DSMC, Sponsor -Investigator discontinues the study because 
of safety considerations.  
• The Sponsor -Investigator defines an administrative or clinical cut -off date.  
 
13.2. Termination  
The study will be terminated when one or more of the following conditions occur:  
If risk -benefit ratio becomes unacceptable owing to, for example:  
• Safety findings from this study (e.g. SAEs)  
• Results of any interim analysis  
• Results of parallel clinical studies  
• Results of parallel animal studies (e.g.  toxicity, teratogenicity,  
       carcinogenicity or reproduction toxicity).  
• If the study conduct (e.g. recruitment rate; drop -out rate; data quality ; 
protocol compliance) does not suggest a proper completion of the trial 
within a reasonable time frame.  
The Sponsor -Investigator has the right to close the trial at any site and at any time.  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
25 
 For any of the above closures, the following applies:  
• Closures should occur only after consultation between involved parties.  
• All affected institutions must be informed as applicable according to local 
law.   
• In case of a partial study closure, ongoing subjects, including those in 
follow -up, must be taken care of in an ethical manner.  
 
 
 
14. RETENTION OF RECORDS  
 
Essential documentation (e.g. adverse events, records of study drug receipt and dispensation), 
including all IRB correspondence, will be retained for at least 2 years after the investigation 
is completed.  Documentation will be readily available upon request.  
 
15. ETHIC AL AND LEGAL ISSUES  
 
15.1. Ethical and Legal Conduct of the Study  
The procedures set out in this protocol, pertaining to the conduct, evaluation, and  
documentation of this study, are designed to ensure that the Investigator abide by Good 
Clinical Practice (GCP)  guidelines and under the guiding principles detailed in the 
Declaration of Helsinki.  The study will also be carried out in keeping with applicable local 
law(s) and regulation(s).  
 
Documented approval from appropriate agencies (e.g. DSMC, IRB, FDA) will b e obtained 
for all participating centers before start of the study, according to GCP, local laws, 
regulations and organizations.  When necessary, an extension, amendment or renewal of IRB 
approval must be obtained and forwarded to Merck (if applicable).  
 
Strict adherence to all specifications laid down in this protocol is required for all aspects of 
study conduct; the Investigators may not modify or alter the procedures described in this 
protocol.   
 
Modifications to the study protocol will not be implement ed by the Sponsor -Investigator 
without discussion and agreement by Merck (if applicable).  However, the Investigators may 
implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) 
to the trial subjects without prior appro val from applicable agencies.  As soon as possible, the 
implemented deviation or change, the reasons for it and if appropriate the proposed protocol 
amendment should be submitted to the appropriate agencies.  Any deviations from the 
protocol must be explai ned and documented by the Investigator.  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
26 
  
The Sponsor -Investigator is responsible for the conduct of the clinical trial at the sites in 
accordance with Title 21 of the Code of Federal Regulations and/or the Declaration of 
Helsinki.  The Sponsor -Investigator  is responsible for personally overseeing the treatment of 
all study subjects.  The Sponsor -Investigator must assure that all study site personnel, 
including sub -investigators and other study staff members, adhere to the study protocol and 
all applicable r egulations and guidelines regarding clinical trials both during and after study 
completion.  
 
The Sponsor -Investigator will be responsible for assuring that all the required data will be 
collected and properly documented.  
 
15.2. Confidentiality  
All records identifying the subject will be kept confidential and, to the extent permitted by 
the applicable laws and/or regulations, will not be made publicly available.  
 
 
 
16. PUBLICATION POLICY  
 
The Investigator must send a draft manuscript of the publication  or abstra ct to Merck Sharp 
& Dohme Corp,  prior to submission of the final version for publication or congress 
presentation. All relevant aspects regarding data reporting and publication will b e part of the 
contract between Merck Sharp & Dohme Corp and the Investiga tor. 
 
The Investigator will ensure that the information regarding the study be publicly available on 
the internet at www.clinicaltrials.gov .  
  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
27 
 REFERENCES  
 1. American Cancer Society. Cancer Facts & Figures 2015. Atlanta: American 
Cancer Society; 2015.  
 2. Piccart -Gebhart MJ, Burzykowski T, Buyse M, et al: Taxanes alone or in 
combination with anthracyclines as first -line therapy of patients with metastatic brea st cancer. J 
Clin Oncol 26:1980 -6, 2008  
 3. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by 3 -hour 
infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575 -
81, 1995  
 4. Nabholtz JM, Gelmon K, B ontenbal M, et al: Multicenter, randomized 
comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin 
Oncol 14:1858 -67, 1996  
 5. Seidman AD, Berry D, Cirrincione C, et al: Randomized phase III trial of weekly 
compared wi th every -3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all 
HER -2 overexpressors and random assignment to trastuzumab or not in HER -2 
nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 
26:1642 -9, 2008  
 6. Mauri D, Kamposioras K, Tsali L, et al: Overall survival benefit for weekly vs. 
three -weekly taxanes regimens in advanced breast cancer: A meta -analysis. Cancer Treat Rev 
36:69 -74, 2010  
 7. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in 
patients with metastatic melanoma. N Engl J Med 363:711 -23, 2010  
 8. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel -T immunotherapy for 
castration -resistant prostate cancer. N Engl J Med 363:411 -22, 2010  
 9. Chen DS , Irving BA, Hodi FS: Molecular pathways: next -generation 
immunotherapy --inhibiting programmed death -ligand 1 and programmed death -1. Clin Cancer 
Res 18:6580 -7, 2012  
 10. Pedoeem A, Azoulay -Alfaguter I, Strazza M, et al: Programmed death -1 pathway 
in cance r and autoimmunity. Clin Immunol 153:145 -52, 2014  
 11. Sheppard KA, Fitz LJ, Lee JM, et al: PD -1 inhibits T -cell receptor induced 
phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. 
FEBS Lett 574:37 -41, 2004  
 12. Yao S, C hen L: PD -1 as an immune modulatory receptor. Cancer J 20:262 -4, 
2014  
 13. Keir ME, Butte MJ, Freeman GJ, et al: PD -1 and its ligands in tolerance and 
immunity. Annu Rev Immunol 26:677 -704, 2008  
 14. Sanmamed MF, Chen L: Inducible expression of B7 -H1 (PD -L1) and its selective 
role in tumor site immune modulation. Cancer J 20:256 -61, 2014  
 15. Topalian SL, Drake CG, Pardoll DM: Immune checkpoint blockade: a common 
denominator approach to cancer therapy. Cancer Cell 27:450 -61, 2015  
 16. Pembrolizumab Investig ator's Brochure. Edition 9.  
 17. Robert C, Ribas A, Wolchok JD, et al: Anti -programmed -death -receptor -1 
treatment with pembrolizumab in ipilimumab -refractory advanced melanoma: a randomised 
dose-comparison cohort of a phase 1 trial. Lancet 384:1109 -17, 20 14 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
28 
  18. Ribas A, Puzanov I, Dummer R, et al: Pembrolizumab versus investigator -choice 
chemotherapy for ipilimumab -refractory melanoma (KEYNOTE -002): a randomised, controlled, 
phase 2 trial. Lancet Oncol 16:908 -18, 2015  
 19. Robert C, Schachter J, Long GV, et al: Pembrolizumab versus Ipilimumab in 
Advanced Melanoma. N Engl J Med 372:2521 -32, 2015  
 20. Nanda R, Chow Q, Dees C, et al. Pembrolizumab in patients with advanced triple -
negative breast cancer: Phase Ib KEYNOTE -012 study. J Clin Oncol.  2016:Published  online on 
May 2, 2016.  
 21. Chen G, Emens LA: Chemoimmunotherapy: reengineering tumor immunity. 
Cancer Immunol Immunother 62:203 -16, 2013  
 22. National Comprehensive Cancer Network Clincal Practice Guidelines in 
Oncology.  Breast.  Version 1.2016.  
 23. DeNardo DG, Brennan DJ, Rexhepaj E, et al: Leukocyte complexity predicts 
breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1:54 -
67, 2011  
 24. Zhang L, Dermawan K, Jin M, et al: Differential impairment of regulatory T cells 
rather than effector T cells by paclitaxel -based chemotherapy. Clin Immunol 129:219 -29, 2008  
 25. Nizar S, Copier J, Meyer B, et al: T -regulatory cell modulation: the future of 
cancer immunotherapy? Br J Cancer 100:1697 -703, 2009  
 26. Chan OT, Yang L X: The immunological effects of taxanes. Cancer Immunol 
Immunother 49:181 -5, 2000  
 27. Kaufmann DE, Walker BD: Programmed death -1 as a factor in immune 
exhaustion and activation in HIV infection. Curr Opin HIV AIDS 3:362 -7, 2008  
 28. Pardoll DM: The blocka de of immune checkpoints in cancer immunotherapy. Nat 
Rev Cancer 12:252 -64, 2012  
 29. Lynch TJ, Bondarenko I, Luft A, et al: Ipilimumab in combination with paclitaxel 
and carboplatin as first -line treatment in stage IIIB/IV non -small -cell lung cancer: resu lts from a 
randomized, double -blind, multicenter phase II study. J Clin Oncol 30:2046 -54, 2012  
 30. Reck M, Bondarenko I, Luft A, et al: Ipilimumab in combination with paclitaxel 
and carboplatin as first -line therapy in extensive -disease -small -cell lung ca ncer: results from a 
randomized, double -blind, multicenter phase 2 trial. Ann Oncol 24:75 -83, 2013  
 31. Rhen T, Cidlowski JA: Antiinflammatory action of glucocorticoids --new 
mechanisms for old drugs. N Engl J Med 353:1711 -23, 2005  
 32. Sparano JA, Wang M, Martino S, et al: Weekly paclitaxel in the adjuvant 
treatment of breast cancer. N Engl J Med 358:1663 -71, 2008  
 33. Markman M, Kennedy A, Webster K, et al: An effective and more convenient 
drug regimen for prophylaxis against paclitaxel -associated hypersen sitivity reactions. J Cancer 
Res Clin Oncol 125:427 -9, 1999  
 34. Berger MJ, Vargo C, Vincent M, et al: Stopping paclitaxel premedication after 
two doses in patients not experiencing a previous infusion hypersensitivity reaction. Support 
Care Cancer 23:2019 -24, 2015  
 35. Quock J, Dea G, Tanaka M, et al: Premedication strategy for weekly paclitaxel. 
Cancer Invest 20:666 -72, 2002  
 36. Mittendorf EA, Philips AV, Meric -Bernstam F, et al: PD -L1 expression in triple -
negative breast cancer. Cancer Immunol Re s 2:361 -70, 2014  
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
29 
  37. Basu GD, Ghazalpour A, Vader R,  et al. Expression of novel immunotherapeutic 
targets in luminal breast cancer patients. Presented at San Antonio Breast Cancer Symposium. 
December 9 -13, 2014. San Antonio, TX. Abstract P5 -04-08.  
 38. Loi S, Sirtaine N, Piette F, et al: Prognostic and predictive value of tumor -
infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node -positive 
breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin -based 
chemotherapy: BIG 02 -98. J Clin Oncol 31:860 -7, 2013  
 39. Adams S, Gray RJ, Demaria S, et al: Prognostic value of tumor -infiltrating 
lymphocytes in triple -negative breast cancers from two phase III randomized adjuvant breast 
cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 32:2959 -66, 2014  
 40. Salgado R, Denkert C, Demaria S, et al: The evaluation of tumor -infiltrating 
lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 
2014. Ann Oncol 26:259 -71, 2015  
 41. Schalper KA: PD -L1 expression and tumor -infiltrating lymphocytes: Revisiting 
the antitumor immune response potential in breast cancer. Oncoimmunology 3:e29288, 2014  
 42. Le DT, Uram JN, Wang H, et al: PD -1 Blockade in Tumors with Mismatch -
Repair Deficiency . N Engl J Med 372:2509 -20, 2015  
 43. Lipson EJ, Velculescu VE, Pritchard TS, et al: Circulating tumor DNA analysis as 
a real -time method for monitoring tumor burden in melanoma patients undergoing treatment with 
immune checkpoint blockade. J Immunother Ca ncer 2:42, 2014  
 
Protocol Number:  LCI-BRE -H2N -PEPP -001 
Version 5: 4/13/20 21 
   
30 
 APPENDICES  
APPENDIX 1: ECOG PERFORMANCE SCALE  
Grade  Description  
0 Normal activity, fully active, able to carry on all p re-disease 
performance without restriction.  
1 Symptoms, but fully ambulatory, restricted in physically 
strenuous but ambulatory and able to carry out work of a light or 
sedentary nature (e .g., light housework, office work).  
2 Ambulatory and capable of all self -care but unable to carry out 
any work activities.  Up and about more than 50% of waking 
hours.  
3 Capable of only limited self -care, confined to bed or chair more 
than 50% of waking hours.  
4 Completely disabled.  Cannot carry on any self -care.  Totally 
confined to bed or chair.  
5 Dead  
 
 